



(51) International Patent Classification:

A61K 39/00 (2006.01) C12N 9/00 (2006.01)

A61K 39/39 (2006.01) C12N 9/12 (2006.01)

A61P 37/00 (2006.01) C12N 15/88 (2006.01)

A61P 37/04 (2006.01)

(21) International Application Number:

PCT/US2023/066974

(22) International Filing Date:

12 May 2023 (12.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/341,987 13 May 2022 (13.05.2022) US

(71) Applicant: CORNER THERAPEUTICS, INC. [US/US];
300 North Beacon Street, Building 39, Suite 202, Water-
town, Massachusetts 02472 (US).

(72) Inventors: GOSSELIN, Emily; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). ZHIVAKI, Dania; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). CHOW, Jonathan; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). NIKIFOROV, Anastasia; c/o Corner Therapeutics, Inc., 300 North Beacon Street, Building 39, Suite 202, Watertown, Massachusetts 02472 (US). SENGUPTA, Debrup; c/o Corner Therapeutics, Inc.,

300 North Beacon Street, Building 39, Suite 202, Water-
town, Massachusetts 02472 (US).


(74) Agent: LEKUTIS, Christine et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MRNA ENCODING A CONSTITUTIVELY-ACTIVE CYCLIC GMP-AMP SYNTHASE AND LIPID DELIVERY VEHICLES FOR SAME

FIG. 11D



(57) Abstract: The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising a pathogen recognition receptor agonist.

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

MRNA ENCODING A CONSTITUTIVELY-ACTIVE CYCLIC GMP-AMP SYNTHASE AND LIPID DELIVERY VEHICLES FOR SAME

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of U.S. Provisional Patent Application No. 63/341,987, filed May 13, 2022, which is incorporated herein by reference in its entirety.

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The content of the electronic sequence listing (165532000540SEQLIST.xml; Size: 22,326 bytes; and Date of Creation: May 10, 2023) is herein incorporated by reference in its entirety.

FIELD

[0003] The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising a pathogen recognition receptor agonist.

BACKGROUND

[0004] Advances in mRNA chemistry and delivery systems have enabled the rapid production of several effective mRNA COVID-19 vaccines (Hou et al., Nature Review Materials, 6:1078-1094, 2021). However, a recent report found that T cell reactivity to the SARS-CoV-2 spike protein is considerably lower in vaccinated, uninfected individuals than in individuals with a prior SARS-CoV-2 infection (Naranbhai et al., Cell, 185:1-11, 2022). This is concerning given that higher levels of SARS-CoV-2-reactive CD4⁺ and CD8⁺ T cell immune responses were found to be associated with milder COVID-19 disease (Rydzynski Moderbacher et al., Cell, 183(4):996-1012, 2020).

[0005] As such, formulations for enhancing cellular immune responses elicited by mRNA vaccines are needed in the art. In particular, adjuvants suitable for increasing adaptive immune responses to nucleic acid-encoded antigens are desirable.

BRIEF SUMMARY

[0006] The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising a pathogen recognition receptor agonist.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] **FIG. 1** is an alignment of amino acid sequences of primate cGASΔN proteins including: human (*Homo sapiens*, SEQ ID NO:1); Rhesus monkey (*Macaca mulatta*, SEQ ID NO:2); olive baboon (*Papio anubis*, SEQ ID NO:3); northern white-cheeked gibbon (*Nomascus leucogenys*, SEQ ID NO:4); common gibbon (*Hylobates lar*, SEQ ID NO:5); Sumatran orangutan (*Pongo abelii*, SEQ ID NO:6); chimpanzee (*Pan troglodytes*, SEQ ID NO:7); western gorilla (*Gorilla gorilla*, SEQ ID NO:8); and a cGASΔN consensus sequence (SEQ ID NO:9).

[0008] **FIG. 2** is a cartoon depicting activation of the stimulator of interferon genes (STING) innate immune signaling pathway by a cyclic GAMP-AMP synthase (cGAS) that has been engineered to be constitutively-active by removal of its amino-terminal phosphoinositide-binding domain. cGASΔN localizes to mitochondria where it binds DNA resulting in the production of cGAMP.

[0009] **FIG. 3A-3C** depict characteristics of lipid nanoparticles (LNPs) produced using GenVoy ILM™ ionizable lipid mix (Precision NanoSystems). **FIG. 3A** shows that LNPs loaded with either OVA, GFP, or cGASΔN mRNAs are all less than 200 nm in diameter. **FIG. 3B** shows that LNPs loaded with either OVA, GFP, or cGASΔN mRNAs are all relatively uniform in size, with all exhibiting a polydispersity index of less than 0.3. **FIG. 3C** shows that LNPs can be loaded with OVA, GFP, or cGASΔN mRNA with similar levels of efficiency.

[0010] **FIG. 4A-4C** show that murine dendritic cells (DCs) secrete inflammatory cytokines stimulated by the cGAS-STING pathway in response to treatment with LNPs loaded with mRNA encoding cGASΔN (cGASΔN LNPs). **FIG. 4A** shows that bone marrow-derived dendritic cells (BMDCs) stimulated with cGASΔN LNPs produce RANTES at significantly higher levels than cells treated with empty LNPs, or only LNPs loaded with mRNA encoding a model antigen. **FIG. 4B** shows that treatment of BMDCs with cGASΔN LNPs results in significantly higher levels of IP-10 secretion than treatment with empty LNPs, or only LNPs loaded with mRNA encoding a model antigen. **FIG. 4C** shows that BMDCs treated with cGASΔN LNPs produce IFNα at significantly higher levels than cells treated with empty LNPs, or only LNPs loaded with mRNA encoding a model antigen. X-axis labels for all three plots are as shown for **FIG. 4C**. $P < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$. Statistics were completed using one-way ANOVA with a Tukey post test for multiple comparisons. Data is representative of two experiments.

[0011] **FIG. 5A-5F** show that treatment with LNPs loaded with mRNA encoding cGASΔN (cGASΔN LNPs) activates murine DCs resulting in increased expression of multiple cell surface markers. DCs were found to express significantly higher levels of co-stimulatory molecules CD40 (**FIG. 5A**), CD86 (**FIG. 5B**), and CD69 (**FIG. 5C**) as shown by increases in mean fluorescence intensity (MFI) following treatment with cGASΔN LNPs as compared to treatment with empty LNPs or only LNPs loaded with mRNA encoding a model antigen. DCs were also found to express significantly higher levels of antigen presentation molecules MHC-II (**FIG. 5D**) and H2kB (MHC-I) (**FIG. 5E**) when treated with cGASΔN LNPs as compared to treatment with empty LNPs or only LNPs loaded with mRNA encoding a model antigen. Additionally, DCs were found to have higher levels of expression of the CCR7 migratory molecule (**FIG. 5F**) when treated with cGASΔN LNPs as compared to treatment with empty LNPs or only LNPs loaded with mRNA encoding a model antigen. X-axis labels for all six plots are as shown for **FIG. 5E** and **FIG. 5F**. $P < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$, $p < 0.0001^{****}$. Statistics were completed using one-way ANOVA with a Tukey post test for multiple comparisons. Data is representative of two experiments.

[0012] **FIG. 6A-6C** show that LNPs made from different lipid formulations and loaded with different mRNAs exhibit similar characteristics. **FIG. 6A** shows that LNPs made

with GenVoy ILM™ ionizable lipid mix (Precision NanoSystems) or with the custom lipid mix are all less than 150 nm in diameter when loaded with OVA, GFP, or cGASΔN mRNA. **FIG. 6B** shows that LNPs made with GenVoy ILM™ or the custom lipid mix are all relatively uniform in size, with a polydispersity index less than 0.3. **FIG. 6C** shows that LNPs made with GenVoy ILM™ or the custom lipid mix allow for efficient encapsulation of OVA, GFP, and cGASΔN mRNAs. Data are representative of three experiments.

[0013] **FIG. 7A-7F** show that cGASΔN mRNA-containing LNPs activate cGAS-STING inflammatory pathways in human monocyte-derived dendritic cells (moDCs). Human moDCs were cultured with LNPs loaded with OVA, GFP, cGASΔN mRNA or a combination of LNPs for 24 hrs, after which supernatants were collected and cytokine secretion was assessed. Human moDCs treated with LNPs loaded with cGASΔN mRNA produced significantly more IL-6 (**FIG. 7A**), more TNFα (**FIG. 7B**), and significantly more IP-10 (**FIG. 7C**) than moDCs treated with LNPs loaded only with mRNA encoding a model antigen. In addition, moDCs secreted significantly more IFNλ1 (**FIG. 7D**) significantly more IFNβ (**FIG. 7E**), and more IFNα2 (**FIG. 7F**) when treated with LNPs loaded with cGASΔN mRNA than moDCs treated with LNPs loaded only with mRNA encoding a model antigen. X-axis labels for all six plots are as shown for **FIG. 7E** and **FIG. 7F**. $P < 0.05^*$, $p < 0.01^{**}$, $p < 0.0001^{***}$. Statistics were completed using two-way ANOVA with a Tukey post test for multiple comparisons. Data is representative of two experiments. Circles show control conditions devoid of LNPs. Squares show conditions including LNPs formed using GenVoy ILM™. Diamonds show conditions including LNPs formed using the custom lipid mix. White squares and white diamonds show conditions including cGASΔN mRNA-containing LNPs formed using GenVoy ILM™ and the custom lipid mix, respectively.

[0014] **FIG. 8A-8D** show that treatment with cGASΔN mRNA-containing LNPs activates human moDCs. Human moDCs were cultured with LNPs loaded with OVA, GFP, cGASΔN mRNA, or a combination of LNPs for 24 hrs, after which cell surface marker expression was measured. CD83 (**FIG. 8A**) expression significantly increased when moDCs were treated with LNPs loaded with cGASΔN mRNA as compared to treatment with LNPs loaded only with mRNA encoding a model antigen. Likewise, expression of T cell costimulatory molecules CD40 (**FIG. 8B**) and CD80 (**FIG. 8C**) significantly increased when moDCs (both

overall population and at the single cell level) were treated with LNPs loaded with cGASΔN mRNA as compared to treatment with LNPs loaded only with mRNA encoding a model antigen. Additionally, MHC Class II (HLA-DR) (**FIG. 8D**) expression was increased when moDCs were treated with cGASΔN mRNA-containing LNPs as compared to treatment with LNPs loaded only with mRNA encoding a model antigen. $P < 0.05^*$, $p < 0.01^{**}$. Statistics completed using two-way ANOVA with a Tukey post test for multiple comparisons. Data is representative of two experiments. Circles show control conditions devoid of LNPs. Squares show conditions including LNPs formed using GenVoy ILM™. Diamonds show conditions including LNPs formed using the custom lipid mix. White squares and white diamonds show conditions including cGASΔN mRNA-containing LNPs formed using GenVoy ILM™ and the custom lipid mix, respectively.

[0015] FIG. 9A-9B show that cGASΔN mRNA-containing LNPs activate inflammatory pathways in a human leukemia monocytic cell line (THP-1 cells). Briefly, THP-1 cells were cultured with LNPs loaded with OVA, GFP, cGASΔN mRNA, or a combination of LNPs for 24 hrs, after which supernatants were collected for measurement of cytokine secretion, and cells were collected for assessment of cell surface molecule expression. THP-1 cells treated with cGASΔN mRNA-containing LNPs secreted significantly more IP-10 (**FIG. 9A**) than THP-1 cells treated with LNPs loaded only with mRNA encoding a model antigen. CD40 expression (**FIG. 9B**) on THP-1 cells increased after treatment with cGASΔN mRNA-containing LNPs as compared to LNPs loaded only with mRNA encoding a model antigen. $P < 0.01^{**}$, $p < 0.0001^{****}$. Statistics were completed using two-way ANOVA with a Tukey post test for multiple comparisons. Data is representative of two experiments. Circles show control conditions devoid of LNPs. Squares show conditions including LNPs formed using GenVoy ILM™. Diamonds show conditions including LNPs formed using the custom lipid mix. White squares and white diamonds show conditions including cGASΔN mRNA-containing LNPs formed using GenVoy ILM™ and the custom lipid mix, respectively.

[0016] FIG. 10A-10B show that treatment of moDCs with R848 in combination with LNPs loaded with mRNA encoding cGASΔN leads to hyperactivation, which is defined by the ability of DCs to secrete IL-1β while remaining viable. moDCs were either left unstimulated (PBS treated), or treated with LNPs loaded with mRNA encoding cGASΔN or OVA in the

presence of media, R848, or R848 and MCC950. **FIG. 10A** shows that all treatment conditions were conducive to viability, indicating that the cells were not pyroptosing in response to any of the treatment conditions. **FIG. 10B** shows that only treatment with LNPs loaded with mRNA encoding cGASΔN, when delivered in combination with R848, stimulated moDCs to secrete IL-1β. Treatment of moDCs with the selective NLRP3 inflammasome inhibitor MCC950 eliminated IL-1β production that would have otherwise been induced by treatment with the cGASΔN mRNA-loaded LNPs in combination with R848. $P < 0.0001$ ****. Statistics were completed using two-way ANOVA with a Tukey post test for multiple comparisons.

[0017] **FIG. 11A-11D** show that administration of LNPs loaded with cGASΔN mRNA increases T cell responses to an mRNA-encoded model antigen delivered via LNP. Mice were immunized twice (prime and boost regimen) with LNPs loaded with 5 mcg mRNA encoding ovalbumin (OVA) delivered in combination with LNPs loaded with 1 mcg or 5 mcg cGASΔN mRNA or loaded with 1 mcg or 5 mcg green fluorescent protein (GFP) mRNA. Blood was collected 7 days post-boost and binding of “SIINFEKL-tetramers” to T cells was subsequently assessed. SIINFEKL is the amino acid sequence (SEQ ID NO:17) of a T cell epitope within OVA. Treatment of mice with LNPs loaded with cGASΔN mRNA in combination with LNPs loaded with mRNA-encoding OVA significantly increased both the frequency (**FIG. 11A**) and absolute number (**FIG. 11C**) of SIINFEKL-specific CD8⁺ T cells in the blood as compared to treatment with LNPs loaded with mRNA encoding OVA and GFP or mRNA encoding GFP and cGASΔN in LNPs prepared using the GenVoy ILM™ formulation. Similarly, treatment of mice with LNPs loaded with cGASΔN mRNA in combination with LNPs loaded with mRNA-encoding OVA significantly increased both the frequency (**FIG. 11B**) and absolute number (**FIG. 11D**) of SIINFEKL-specific CD8⁺ T cells in the blood as compared to treatment with LNPs loaded with mRNA encoding OVA and GFP in LNPs prepared using the custom lipid mix. $P < 0.01$ **, $p < 0.001$ ***. Statistics for GenVoy ILM™ plots were completed using two-way ANOVA with a Tukey post test for multiple comparisons. Statistics for the custom lipid mix were completed using an unpaired t test.

[0018] **FIG. 12A-12F** show that treatment with LNPs loaded with cGASΔN mRNA reduces Th2 specific antibodies without impacting total IgG responses. Mice were immunized twice with LNPs loaded with 5 mcg OVA mRNA delivered with LNPs loaded with 1 mcg or

5 mcg cGASΔN mRNA or LNPs loaded with 1 mcg or 5 mcg of GFP mRNA. Blood was collected 7 days post-boost and serum was isolated to quantify antibody responses. Mice treated with LNPs loaded with OVA and cGASΔN mRNA did not show significant changes in OVA-specific total IgG as compared to mice treated with LNPs loaded with OVA mRNA and GFP mRNA in LNPs prepared using the GenVoy ILM™ formulation (**FIG. 12A**) and in LNPs prepared using the custom lipid mix (**FIG. 12B**). As shown in **FIG. 12C**, OVA-specific IgG1 was significantly reduced by the presence cGASΔN mRNA in LNPs prepared using GenVoy ILM™ formulation ($p < 0.05$ for the 1:500 and 1:2500 dilution, 1 mcg and 5 mcg cGASΔN mRNA-containing LNPs versus GFP mRNA-containing LNPs. As shown in **FIG. 12D**, OVA-specific IgG1 responses were reduced in mice treated with cGASΔN mRNA-containing LNPs prepared using the custom lipid mix ($p < 0.05$ for the 1:500, 1:2500, and 1:12500 dilution at 5 mcg cGASΔN mRNA-containing LNPs versus GFP mRNA-containing LNPs. In contrast, mice treated with OVA mRNA containing and cGASΔN LNPs did not show significant changes in OVA-specific IgG2a measured compared to OVA + GFP LNP treatment when LNPs were prepared with the GenVoy (E) and custom lipid mix (F) formulations. Legend at top applies to all panels. Statistics were completed using two-way ANOVA with a Tukey post test for multiple comparisons

[0019] **FIG. 13A** shows structures of cationic and ionizable lipids suitable for use in the lipid-based mRNA delivery vehicles of the present disclosure. **FIG. 13B** shows structures of other types of lipids suitable for use in the lipid-based mRNA delivery vehicles of the present disclosure. See also, Hou et al., Nature Review Materials, 6:1078-1094, 2021, which is incorporated herein by reference.

DETAILED DESCRIPTION

[0020] The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising a pathogen recognition receptor

agonist. In some embodiments, the compositions of the present disclosure do not comprise a lysophosphatidylcholine (LPC) with a single C13-C24 acyl chain.

[0021] Inducing an inflammatory response can be desirable, such as for an immunotherapy or vaccination. COVID-19 mRNA vaccines (comprising LNPs loaded with mRNA encoding a SARS-CoV-2 antigen) have proven to be effective at reducing frequency and severity of infections. As described herein, inducing the cGAS-STING innate immune pathway adjuvants compositions comprising LNPs loaded with mRNA encoding a protein antigen, which in exemplary embodiments is ovalbumin (OVA). STING signaling is of particular interest out of all possible innate immune signaling pathways because, unlike some other signaling pathways, cGAS-STING activation does not induce translation inhibition.

[0022] In order to induce cGAS-STING signaling, a cGAS mutant lacking a portion of its N-terminus was designed such that it is constitutively active (cGAS Δ N). mRNA encoding the cGAS mutant was packaged in an LNP for cellular uptake and protein expression. The LNP-packaged mRNA encoding cGAS Δ N has the ability to adjuvant an immune response via the cGAS-STING pathway. Importantly, inclusion of mRNA encoding a constitutively active cGAS, such as cGAS Δ N, increases the potency of LNPs loaded with mRNA encoding an antigen by increasing inflammatory signals.

General Techniques and Definitions

[0023] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.

[0024] As used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural references unless indicated otherwise. For example, “an” excipient includes one or more excipients.

[0025] The phrase “comprising” as used herein is open-ended, indicating that such embodiments may include additional elements. In contrast, the phrase “consisting of” is closed, indicating that such embodiments do not include additional elements (except for trace impurities). The phrase “consisting essentially of” is partially closed, indicating that such

embodiments may further comprise elements that do not materially change the basic characteristics of such embodiments.

[0026] The term “about” as used herein in reference to a value, encompasses from 90% to 110% of that value (e.g., a molecular weight of about 900 daltons, refers to a molecular weight of from 810 daltons to 990 daltons).

[0027] An “effective amount” or a “sufficient amount” of a substance is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied. For instance, in the context of administering an immunogenic composition comprising one or more mRNAs encoding an antigen and a constitutively-active cGAS, an effective amount contains sufficient mRNA, to stimulate an immune response against the antigen (e.g., antigen-reactive antibody and/or cellular immune response).

[0028] The terms “individual” and “subject” refer to mammals. “Mammals” include, but are not limited to, humans, non-human primates (e.g., monkeys), farm animals, sport animals, rodents (e.g., mice and rats), and pets (e.g., dogs and cats). In some embodiments, the subject is a human patient, such as a human patient suffering from cancer and/or an infectious disease.

[0029] The term “dose” as used herein in reference to an immunogenic composition refers to a measured portion of the immunogenic composition taken by (administered to or received by) a subject at any one time.

[0030] The terms “isolated” and “purified” as used herein refers to a material that is removed from at least one component with which it is naturally associated (e.g., removed from its original environment). As an example, when used in reference to a phospholipid, an isolated phospholipid is at least 90%, 95%, 96%, 97%, 98% or 99% pure as determined by thin layer chromatography, or gas chromatography. As a further example, when used in reference to a recombinant protein, an isolated protein refers to a protein that has been removed from the culture medium of the host cell that produced the protein.

[0031] The terms “pharmaceutical formulation” and “pharmaceutical composition” refer to preparations that are in such form as to permit the biological activity of the active

ingredient to be effective, and that contain no additional components that are unacceptably toxic to an individual to which the formulation or composition would be administered. Such formulations or compositions are intended to be sterile.

[0032] “Excipients” as used herein include pharmaceutically acceptable excipients, carriers, vehicles or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable excipient is an aqueous pH buffered solution.

[0033] The term “antigen” refers to a substance that is recognized and bound specifically by an antibody or by a T cell antigen receptor. Antigens can include peptides, polypeptides, proteins, glycoproteins, polysaccharides, complex carbohydrates, sugars, gangliosides, lipids and phospholipids; portions thereof and combinations thereof. In the context of the present disclosure, the term “antigen” typically refers to a polypeptide encoded by a nucleic acid sequence of a mRNA or a DNA. Polypeptide antigens are preferably at least eight amino acid residues in length, and may comprise one or more post-translational modifications.

[0034] The term “agonist” is used in the broadest sense and includes any molecule that activates signaling through a receptor. In some embodiments, the agonist binds to the receptor. For instance, a TLR8 agonist binds to a TLR8 and activates a TLR8-signaling pathway.

[0035] “Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups. C_x alkyl refers to an alkyl group having x number of carbon atoms. C_x-C_y alkyl or C_x-y alkyl refers to an alkyl group having between x number and y number of carbon atoms, inclusive.

[0036] “Alkylene” refers to divalent saturated aliphatic hydrocarbyl groups.

[0037] “Alkenyl” refers to monovalent hydrocarbyl groups having at least one double bond (>C=C<). C_x alkenyl refers to an alkenyl group having x number of carbon atoms. C_x-C_y alkenyl or C_x-y alkenyl refers to an alkenyl group having between x number and y number of carbon atoms, inclusive.

[0038] “Stimulation” of a response or parameter includes eliciting and/or enhancing that response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition (e.g., increase in TLR-signaling in

the presence of a TLR agonist as compared to the absence of the TLR agonist). For example, “stimulation” of an immune response means an increase in the response. Depending upon the parameter measured, the increase may be from 2-fold to 2,000-fold, or from 5-fold to 500-fold or over, or from 2, 5, 10, 50, or 100-fold to 500, 1,000, 2,000, 5,000, or 10,000-fold.

[0039] Conversely, “inhibition” of a response or parameter includes reducing and/or repressing that response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition (e.g., decrease in abnormal cell proliferation after administration of a composition of the present disclosure as compared to the administration of a placebo composition or no treatment). For example, “inhibition” of an immune response means a decrease in the response. Depending upon the parameter measured, the decrease may be from 2-fold to 2,000-fold, or from 5-fold to 500-fold or over, or from 2, 5, 10, 50, or 100-fold to 500, 1,000, 2,000, 5,000, or 10,000-fold.

[0040] The relative terms “higher” and “lower” refer to a measurable increase or decrease, respectively, in a response or parameter when compared to otherwise same conditions except for a parameter of interest, or alternatively, as compared to another condition. For instance, a “higher level of DC hyperactivation” refers to a level of DC hyperactivation as a consequence of a treatment condition that is at least 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold above a level of DC hyperactivation as a consequence of a control condition. Likewise, a “lower level of DC hyperactivation” refers to a level of DC hyperactivation as a consequence of a treatment condition that is at least 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold below a level of DC hyperactivation as a consequence of a control condition.

[0041] As used herein the term “immunization” refers to a process that increases a mammalian subject’s immune response to an antigen and therefore improves its ability to resist or overcome infection and/or resist disease.

[0042] The term “vaccination” as used herein refers to the introduction of vaccine into a body of a mammalian subject.

[0043] “Adjuvant” refers to a substance which, when added to a composition comprising an antigen or a nucleic acid encoding an antigen, enhances or potentiates an immune response to the antigen in the mammalian recipient upon exposure.

[0044] The terms “treating” or “treatment” of a disease refer to executing a protocol, which may include administering one or more therapeutic agents to an individual (human or otherwise), in an effort to obtain beneficial or desired results in the individual, including clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more signs or symptoms of a disease, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total). “Treatment” also can mean prolonging survival as compared to expected survival of an individual not receiving treatment. Further, “treating” and “treatment” may occur by administration of one dose of a therapeutic agent or therapeutic agents, or may occur upon administration of a series of doses of a therapeutic agent or therapeutic agents. “Treating” or “treatment” does not require complete alleviation of signs or symptoms, and does not require a cure, and specifically includes protocols that have only a palliative effect on the individual. “Palliating” a disease or disorder means that the extent and/or undesirable clinical manifestations of the disease or disorder are lessened and/or time course of progression of the disease or disorder is slowed, as compared to the expected untreated outcome.

[0045] The term “constitutively-active” as used herein in reference to cGAS refers to a cGAS variant that binds to DNA in the cytoplasm and catalyzes cGAMP synthesis even under some conditions in which native cGAS has little to no enzymatic activity. In some preferred embodiments, the “constitutively-active cGAS” is a “truncated cGAS”, such as cGAS Δ N comprising a C-terminal DNA-binding, enzymatic domain in the absence of a N-terminal disordered domain. That is, cGAS Δ N is a constitutively-active cGAS devoid of regulation of enzymatic activity imparted by the N-terminal disordered domain of full length cGAS.

I. Constitutively-Active Cyclic GMP-AMP Synthase

[0046] Cyclic GMP-AMP synthase, also referred to as cGAMP synthase or cGAS, is an enzymatic sensor of cytosolic DNA. cGAS recognizes double-stranded DNA independent of its sequence resulting in dimerization, formation of liquid-like droplets and production of the secondary messenger 2'3'cyclic GMP-AMP (cGAMP), which binds to and activates STING resulting in expression of interferons and other inflammatory mediators. Specifically, STING

activation results in a signaling cascade that ultimately activates IRF3 and NF- κ B transcription factors. IRF3 activation leads to the expression of genes such as IP-10 and Type I interferons that induce antiviral immune responses. NF- κ B activation induces the expression of inflammatory cytokines such as IL-6 that enhance inflammatory immune responses.

[0047] Human cGAS is 522 amino acids in length, including a N-terminal phosphoinositide-binding domain (residues 1-59) and a C-terminal DNA-binding and enzymatic domain (residues 160-522) (Barnett et al., Cell, 176:1432-1446, 2019). Importantly, expression of cGAS Δ N in a human leukemia monocytic cell line was found to result in higher levels of expression of interferon and interferon-stimulated genes (Barnett, supra, 2019).

[0048] The amino acid sequence of human cGAS (GenBank No. NP_612450.2) is:
 MQPWHGKAMQRASEAGATAPKASARNARGAPMDPTESPAAPEAALPKAGKFGPARKSGSRQKKSAPDTQE
 RPPVVRATGARAKKAPQRAQDTQPSDATSAPGAEGLEPPAAREPALS RAGSCRQRGARCSTKPRPPPGPWD
 VPSPGLPVSAPILVRRDAAPGASKLRVLEKLEKLSRDDISTAAGMVKGVDHLLRLKCDSA FRGVGLLN
 TGSYYEHVKISAPNEFDVMFKLEV PRIQLEEYSNTRAYYFVKFKRNPKENPLSQFLEGEILSASKMLSKF
 RKIIKEEINDIKD TDVIMKRKRGGSPAVTLLISEKISVDITLALESKSSWPASTQEGLRIQNWLSAKVRK
 QLRLKPFYLVPKHAKENG FQEETWRLSF SHIEKEILNNHGKSKTCCENKEEKCCRKDCLKLMKYLLLEQL
 KERFKDKKHLDFESSYHVKT AFFHVCTQNPQDSQWDRKDLGLCFDNCVTYFLQCLRTEKLENYFIPEFNL
 FSSNLIDKRSKEFLTKQIEYERNNEFPVFDEF (SEQ ID NO:10).

[0049] The amino acid sequence of the N-terminal domain of cGAS is:
 MQPWHGKAMQRASEAGATAPKASARNARGAPMDPTESPAAPEAALPKAGKFGPARKSGSRQKKSAPDTQE
 RPPVVRATGARAKKAPQRAQDTQPSDATSAPGAEGLEPPAAREPALS RAGSCRQRGARCSTKPRPPPGPWD
 VPSPGLPVSAPILVRRDAA (SEQ ID NO:11).

[0050] The amino acid sequence of the C-terminal domain of cGAS (cGAS Δ N) is:
 PGASKLRVLEKLEKLSRDDISTAAGMVKGVDHLLRLKCDSA FRGVGLLNTGSYYEHVKISAPNEFDVM
 FKLEV PRIQLEEYSNTRAYYFVKFKRNPKENPLSQFLEGEILSASKMLSKFRKIIKEEINDIKD TDVIMK
 RKRGGSPAVTLLISEKISVDITLALESKSSWPASTQEGLRIQNWLSAKVRKQLRLKPFYLVPKHAKENG
 FQEETWRLSF SHIEKEILNNHGKSKTCCENKEEKCCRKDCLKLMKYLLLEQLKERFKDKKHLDFESSYHVK
 T AFFHVCTQNPQDSQWDRKDLGLCFDNCVTYFLQCLRTEKLENYFIPEFNL FSSNLIDKRSKEFLTKQIE
 YERNNEFPVFDEF (SEQ ID NO:1).

[0051] The nucleotide sequence encoding human cGAS Δ N, which was codon-optimized for expression in mouse cells is set forth as SEQ ID NO:17. A DNA template with this nucleotide sequence was used to prepare mRNA encoding human cGAS Δ N, which was loaded into LNPs and tested as described in Examples 1, 2 and 3.

[0052] Compositions and methods of the present disclosure comprise a nucleic acid encoding a constitutively-active cGAS as a catalytic adjuvant for improving adaptive immune responses elicited by mRNA vaccines. In some preferred embodiments, the constitutively-active cGAS is a truncated cGAS devoid of the N-terminal phosphoinositide-binding domain (cGAS Δ N). In some preferred embodiments, the constitutively-active cGAS is a truncated cGAS comprising the C-terminal DNA-binding and enzymatic domain (cGAS Δ N).

[0053] Homologs of cGAS are expressed in species across the animal kingdom, and cGAS amino acid sequences are conserved in higher primates. An alignment of the amino acid sequence of the c-terminal domain of human cGAS with the amino acid sequences of the c-terminal domains of multiple non-human primate cGAS proteins is shown in **FIG. 1**.

Table I. Percent Identity Matrix Created by Clustal 12.1[^]

#	Species	1	2	3	4	5	6	7	8
1	M._mulatta	100.00	96.42	87.53	85.95	88.71	87.26	86.78	86.50
2	P._anubis	96.42	100.00	87.53	86.23	88.98	88.09	87.88	87.33
3	N._leucogenys	87.53	87.53	100.00	96.14	93.37	89.97	90.03	90.30
4	H._lar	85.95	86.23	96.14	100.00	92.31	88.92	88.98	88.71
5	P._abelii	88.71	88.98	93.37	92.31	100.00	93.07	93.39	92.84
6	P._troglodytes	87.26	88.09	89.97	88.92	93.07	100.00	97.51	96.95
7	H._sapiens	86.78	87.88	90.03	88.98	93.39	97.51	100.00	98.35
8	G._gorilla	86.50	87.33	90.30	88.71	92.84	96.95	98.35	100.00

[^]Numbers in this table are not SEQ ID NOS.

[0054] In some preferred embodiments, the constitutively-active cGAS is a truncated human cGAS devoid of the N-terminal domain (SEQ ID NO:11). In some preferred embodiments, the constitutively-active cGAS is a truncated human comprising the C-terminal domain (SEQ ID NO:1). In some preferred embodiments, cGAS Δ N comprises the amino acid sequence of SEQ ID NO:1 or the amino acid sequence that is at least 85%, 90%, 95%, 96%,

97%, 98% or 99% identical to SEQ ID NO:1. In some preferred embodiments, cGASΔN comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, or the amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8. In some preferred embodiments, cGASΔN comprises the consensus amino acid sequence of SEQ ID NO:9. For expression in transfected cells, the nucleic acid encoding cGASΔN is in operable combination with a start codon (ATG).

[0055] “Percent (%) sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, the % sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y, where X is the number of amino acid residues scored as identical matches by the sequence in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % sequence identity of A to B will not equal the % sequence identity of B to A.

II. mRNA Encoding An Antigen

[0056] Compositions and methods of the present disclosure may comprise an mRNA encoding an antigen or are otherwise suitable for use with a formulation comprising an mRNA

encoding an antigen. In some embodiments, the antigen is a proteinaceous antigen. The terms “polypeptide” and “protein” are used interchangeably herein in reference to antigens that comprise peptide chains that are at least 8 amino acids in length. In some embodiments, the antigen is from 8 to 1800 amino acids, 9 to 1000 amino acids, or 10 to 100 amino acids in length. The polypeptide may be post-translationally modified such as by phosphorylation, hydroxylation, sulfonation, palmitoylation, and/or glycosylation.

[0057] In some embodiments, the antigen is a tumor antigen that comprises the amino acid sequence of at least one full length protein or fragment thereof. In some embodiments, the tumor antigen comprises an amino acid sequence or fragment thereof from an oncoprotein. In some embodiments, the mammalian antigen is a neoantigen or encoded by a gene comprising a mutation relative to the gene present in normal cells from a mammalian subject. Neoantigens are thought to be particularly useful in enabling T cells to distinguish between cancer cells and non-cancer cells (see, e.g., Schumacher and Schreiber, *Science*, 348:69-74, 2015). In other embodiments, the tumor antigen comprises a viral antigen, such as an antigen of a cancer-causing virus.

[0058] In some embodiments, the tumor antigen is a fusion protein comprising two or more polypeptides, wherein each polypeptide comprises an amino acid sequence from a different tumor antigen or non-contiguous amino acid sequences from the same tumor antigen. In some of these embodiments, the fusion protein comprises a first polypeptide and a second polypeptide, wherein each polypeptide comprises non-contiguous amino acid sequences from the same tumor antigen.

[0059] In some embodiments, the antigen is a microbial antigen. In some embodiments, the microbial antigen comprises a viral antigen, a bacterial antigen, a protozoan antigen, a fungal antigen, or combinations thereof. In some embodiments, the microbial antigen comprises a surface protein or other antigenic subunit of a microbe.

[0060] In some preferred embodiments, the mRNA comprises a 5' untranslated region (5'UTR) at the 5' end of the coding region and a 3' untranslated region (3'UTR) at the 3' end of the coding region. In some preferred embodiments, the mRNA comprises one or both of a 5' cap structure and a polyA tail.

[0061] In some embodiments the mRNA further encodes a ribosome skipping sequence, such as the 2A-like sequence set forth as SEQ ID NO:12. Additional 2AL sequences are set forth in SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15. In some embodiments in which the mRNA comprises two or more coding regions, the coding regions may be separated by a 2AL sequence. For instance, the 2AL sequence may be located between the coding region of constitutively active cyclic GMP-AMP synthase (cGAS), and the coding region of an antigen (e.g., cGAS Δ Ns-2AL-antigen or antigen-2AL-cGAS Δ N). Similarly, in some embodiments in which the mRNA comprises coding regions for two or more antigens, the coding regions may be separated by a 2AL sequence (e.g., antigen1-2AL-antigen2). Additional 2AL sequence for use in mRNAs of the present disclosure are known in the art (see, e.g., Luke et al., J. Gen. Virol., 89:1036-1042, 2008, 2AL sequences of Figure 2 are incorporated herein by reference).

III. Lipid-Based Delivery Vehicles

[0062] Compositions and methods of the present disclosure may comprise a lipid-based delivery vehicle for an mRNA vaccine. In some embodiments, the vehicle is a lipid nanoparticle (LNP). In other embodiments, the vehicle is a lipid that forms a complex with the mRNA (RNA-Lipoplex).

[0063] In some embodiments, the LNP comprises at least one lipid selected from the group consisting of an ionizable lipid, a cationic lipid, a phospholipid, a pegylated lipid, a structural lipid, and mixtures thereof. In some embodiments, the at least one lipid comprises an ionizable lipid. In some embodiments, the at least one lipid comprises a cationic lipid. In some embodiments, the at least one lipid comprises a phospholipid. In some embodiments, the at least one lipid comprises a pegylated lipid. In some embodiments, the at least one lipid comprises a structural lipid. In some embodiments, the at least one lipid comprise an ionizable lipid, a phospholipid, a pegylated lipid, and a structural lipid.

[0064] In some embodiments, the lipid component of RNA-Lipoplex comprises one or more lipids. In some preferred embodiments, the one or more lipids comprise a first lipid and a second lipid, wherein the first lipid is distinct from the second lipid. In some embodiments, the first lipid is a cationic lipid and the second lipid is a neutral or anionic lipid.

[0065] Structures of lipids suitable for use in the lipid-based mRNA delivery vehicles of the present disclosure are depicted in **FIG. 13A** and **FIG. 13B**, which are adapted from Figure 2 of Hou et al., Nature Review Materials, 6:1078-1094, 2021.

IV. Pathogen Recognition Receptor Agonists

[0066] Compositions and methods of the present disclosure may comprise a further pathogen recognition receptor (PRR) agonist. In some embodiments, the PRR agonist comprises an agonist of a toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor (RLR), or a C-type lectin receptor (CLR). In some embodiments, the PRR agonist comprises a TLR7/8 agonist.

A. TLR7/8 Agonists

[0067] The term “TLR7/8 agonist” as used herein refers to an agonist of TLR7 and/or TLR8. In one aspect, the TLR7/8 agonist is a TLR7 agonist. In another aspect, the TLR7/8 agonist is a TLR8 agonist. In a further aspect, the TLR7/8 agonist is an agonist of both TLR7 and TLR8. TLR7/8 agonists of the present disclosure are suitable for hyperactivating human dendritic cells in the presence of a DAMP such as oxPAPC or PGPC.

[0068] In some aspects, the TLR7/8 agonist is a small molecule. In some embodiments, the TLR7/8 agonist is a small molecule with a molecule weight of 900 daltons or less, or a salt thereof. That is, the small molecule TLR7/8 agonist is not a large molecule like a recombinant protein or a synthetic oligonucleotide, which is regulatable by the U.S. FDA’s Center for Biologics Evaluation and Research. Rather the small molecule TLR7/8 agonist is regulatable by the FDA’s Center for Drug Evaluation and Research. In some embodiments, the small molecule has a molecule weight of from about 90 to about 900 daltons. In some embodiments, the TLR7/8 agonist comprises an imidazoquinoline compound. In some preferred embodiments, the TLR7/8 agonist comprises resiquimod (R848).

B. Other PRR Agonists

[0069] In some aspects, the pathogen recognition receptor (PRR) agonist comprises a toll-like receptor (TLR) agonist with the proviso that the TLR agonist does not comprise a TLR7/8 agonist. In some embodiments, the TLR agonist comprises an agonist of one or more of

TLR2, TLR3, TLR4, TLR5, TLR9 and TLR13. In some embodiments, the PRR agonist is a TLR2/6 agonist, such as Pam2CSK4. In other embodiments, the TLR agonist is a TLR4 agonist such as monophosphoryl lipid A (MPLA). However, in preferred embodiments, the TLR agonist is not an agonist of TLR2, TLR4 and/or TLR9. For instance, in preferred embodiments, the TLR9 agonist is not a TLR4 ligand such as LPS (endotoxin).

[0070] In other aspects, the PRR agonist comprises a NOD-like receptor (NLR) agonist. In further aspects, the PRR agonist comprises a RIG-I-like receptor (RLR) agonist. In additional aspects, the PRR agonist comprises a C-type lectin receptor (CLR) agonist.

V. Pharmaceutical Formulations

[0071] Some compositions of the present disclosure are pharmaceutical formulations comprising a pharmaceutically acceptable excipient. Pharmaceutical formulations of the present disclosure may be in the form of a solution or a suspension. Alternatively, the pharmaceutical formulations may be a dehydrated solid (e.g., freeze dried or spray dried solid). The pharmaceutical formulations of the present disclosure are preferably sterile, and preferably essentially endotoxin-free. The term “pharmaceutical formulations” is used interchangeably herein with the terms “medicinal product” and “medicament”. In some embodiments, the pharmaceutical formation comprises specific ratios of the various components based on the intended purpose of the formulation.

[0072] Pharmaceutically acceptable excipients of the present disclosure include for instance, solvents, buffering agents, tonicity adjusting agents, bulking agents, and preservatives (*See, e.g.*, Pramanick et al., *Pharma Times*, 45:65-77, 2013). In some embodiments, the pharmaceutical formulations may comprise an excipient that functions as one or more of a solvent, a buffering agent, a tonicity adjusting agent, and a bulking agent (e.g., sodium chloride in saline may serve as both an aqueous vehicle and a tonicity adjusting agent).

[0073] In some embodiments, the pharmaceutical formulations comprise an aqueous vehicle as a solvent. Suitable vehicles include for instance sterile water, saline solution, phosphate buffered saline, and Ringer's solution. In some embodiments, the composition is isotonic.

[0074] The pharmaceutical formulations may comprise a buffering agent. Buffering agents control pH to inhibit degradation of the active agent during processing, storage and optionally reconstitution. Suitable buffers include for instance salts comprising acetate, citrate, phosphate or sulfate. Other suitable buffers include for instance amino acids such as arginine, glycine, histidine, and lysine. The buffering agent may further comprise hydrochloric acid or sodium hydroxide. In some embodiments, the buffering agent maintains the pH of the composition within a range of 6 to 9. In some embodiments, the pH is greater than (lower limit) 6, 7 or 8. In some embodiments, the pH is less than (upper limit) 9, 8, or 7. That is, the pH is in the range of from about 6 to 9 in which the lower limit is less than the upper limit.

[0075] The pharmaceutical compositions may comprise a tonicity adjusting agent. Suitable tonicity adjusting agents include for instance dextrose, glycerol, sodium chloride, glycerin and mannitol.

[0076] The pharmaceutical formulations may comprise a bulking agent. Bulking agents are particularly useful when the pharmaceutical composition is to be lyophilized before administration. In some embodiments, the bulking agent is a protectant that aids in the stabilization and prevention of degradation of the active agents during freeze or spray drying and/or during storage. Suitable bulking agents are sugars (mono-, di- and polysaccharides) such as sucrose, lactose, trehalose, mannitol, sorbitol, glucose and raffinose.

[0077] The pharmaceutical formulations may comprise a preservative. Suitable preservatives include for instance antioxidants and antimicrobial agents. However, in preferred embodiments, the pharmaceutical formulation is prepared under sterile conditions and is in a single use container, and thus does not necessitate inclusion of a preservative.

[0078] The pharmaceutical formulations of the present disclosure are suitable for parenteral administration. That is the pharmaceutical formulations of the present disclosure are not intended for enteral administration (e.g., not by orally, gastrically, or rectally).

VI. Methods of Use

[0079] In some aspects, the present disclosure relates to methods of use of any one of the compositions or formulations described herein. The methods of use are suitable for a plurality of uses involving stimulating an immune response. In some embodiments, the methods

of use comprise methods of treating cancer. In some embodiments, the methods of use comprise methods of inhibiting abnormal cell proliferation. In some embodiments, the methods of use comprise methods of treating or preventing an infectious disease. The methods comprise administering an effective amount of a formulation or a composition described herein to an individual in need thereof to achieve a specific outcome. The individual is a mammalian subject, such as a human patient. In other embodiments, the individual a non-human patient. In some embodiments, the individual is a canine patient. That is in some embodiments, the methods of use involve clinical uses, while in other embodiments the methods of use involve pre-clinical and/or veterinary uses. For preclinical uses, the mammalian subject may be a non-human primate (e.g., monkey or ape) or a rodent (e.g., mouse or rat). For veterinary uses the mammalian subject may be a farm animal (e.g., cow), a sport animal (e.g., horse), a or a pet (e.g., companion animal such as a dog or cat).

A. Stimulation of an Immune Response

[0080] In brief, the present disclosure provides methods of stimulating an immune response in an individual, comprising administering to the individual a composition or formulation described herein in an amount sufficient to stimulate an immune response in the individual. “Stimulating” an immune response (used interchangeably with “eliciting” and immune response), means increasing the immune response, which can arise from eliciting a de novo immune response (e.g., as a consequence of an initial vaccination regimen) or enhancing an existing immune response (e.g., as a consequence of a booster vaccination regimen). In some embodiments, stimulating an immune response comprises one or more of the group consisting of: stimulating cytokine production; stimulating B lymphocyte proliferation; stimulating interferon pathway-associated gene expression; stimulating chemoattractant-associated gene expression; and stimulating dendritic cell DC maturation. Methods for measuring stimulation of an immune response are known in the art.

[0081] For instance, the present disclosure provides methods of inducing an antigen-specific immune response in an individual by administering to the individual a composition or formulation described herein in an amount sufficient to induce an antigen-specific immune response in the individual. In preferred embodiments, the composition or formulation comprises

the antigen. In some embodiments, the composition or formulation is administered to a tissue of the individual comprising the antigen. The immune response may comprise one or more of an antigen-specific antibody response, an antigen-specific cytotoxic T lymphocyte (CTL) response, and an antigen-specific helper T (Th) cell response. “Inducing” an antigen-specific antibody response means increasing titer of the antigen-specific antibodies above a threshold level such as a pre-administration baseline titer or a seroprotective level. “Inducing” an antigen-specific CTL response means increasing frequency of antigen-specific CTL found in peripheral blood above a pre-administration baseline frequency. “Inducing” an antigen-specific Th cell response means increasing frequency of antigen-specific Th cells found in peripheral blood above a pre-administration baseline frequency.

[0082] Analysis (both qualitative and quantitative) of the immune response can be by any method known in the art, including, but not limited to, measuring antigen-specific antibody production (including measuring specific antibody subclasses), activation of specific populations of lymphocytes such as B cells and helper T cells, production of cytokines such as IFN-alpha, IFN-gamma, IL-6, IL-12 and/or release of histamine. Methods for measuring antigen-specific antibody responses include enzyme-linked immunosorbent assay (ELISA). Activation of specific populations of lymphocytes can be measured by proliferation assays, and with fluorescence-activated cell sorting (FACS). Production of cytokines can also be measured by ELISA. In some embodiments, methods of stimulating an immune response comprise stimulation of interleukin-1beta (IL-1 β) secretion, interferon-gamma (IFN- γ) secretion, and/or tumor necrosis factor-alpha (TNF- α) secretion by monocyte-derived dendritic cells or peripheral blood mononuclear cells. In some preferred embodiments, at least 50%, 55%, 60%, 65%, 70% or 75% of the cells contacted with a composition of the present disclosure remain viable at 40-56 hours (or about 48 hours) post-contact.

[0083] In some embodiments, the methods are suitable for stimulating an anti-tumor immune response. In other embodiments, the methods are suitable for stimulating an anti-microbe immune response. In some embodiments, the anti-microbe response is an anti-bacterial immune response. In some embodiments, the anti-microbe response is an anti-fungal immune response. In some embodiments, the anti-microbe response is, an anti-viral immune response. In some embodiments, the anti-microbe response is an anti-protozoan immune response.

B. Treating or Preventing Disease

[0084] The present disclosure further provides methods of treating or preventing a disease in an individual, comprising administering to the individual a composition or formulation described herein in an amount sufficient to treat or prevent a disease in the individual. In some embodiments, the disease is cancer. In some embodiments, the disease is abnormal cell proliferation. In other embodiments, the disease is an infectious disease.

[0085] In some embodiments, the methods involve treating cancer in an individual or otherwise treating a mammalian subject with cancer. In some embodiments, the cancer is a hematologic cancer, such as a lymphoma, a leukemia, or a myeloma. In other embodiments, the cancer is a non-hematologic cancer, such as a sarcoma, a carcinoma, or a melanoma. In some embodiments, the cancer is malignant.

[0086] In some embodiments, the methods involve inhibiting abnormal cell proliferation in an individual. “Abnormal cell proliferation” refers to proliferation of a benign tumor or a malignant tumor. The malignant tumor may be a metastatic tumor.

[0087] In some embodiments, the methods involve treating or preventing an infectious disease in an individual. In some embodiments, the infectious disease is caused by a viral infection. In other embodiments, the infectious disease is caused by a bacterial infection. In further embodiments, the infectious disease is caused by a fungal infection. In still further embodiments, the infectious disease is caused by a protozoal infection. Of particular importance are infectious diseases caused by zoonotic pathogens that infect humans as well as other animals such as mammals or birds. In some embodiments, the zoonotic pathogen is transmitted to humans via an intermediate species (vector).

Enumerated Embodiments

In this section, Embodiment 1 refers to both Embodiment 1’ and Embodiment 1”

1’. A composition comprising a first mRNA encapsulated in a first lipid nanoparticle (LNP) and a second mRNA encapsulated in a second LNP,

wherein the first mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS),

wherein the second mRNA comprises a coding region of an antigen, and

wherein both the first LNP and the second LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

1". A composition comprising an mRNA encapsulated in a lipid nanoparticle (LNP), wherein the mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof, optionally wherein the composition further comprises a further mRNA encapsulated in a further lipid nanoparticle, and the further mRNA comprises a coding region of an antigen of interest and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

2. A composition comprising a first mRNA and a second mRNA encapsulated in a lipid nanoparticle (LNP), wherein the first mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), the second mRNA comprises a coding region of an antigen; and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

3. A composition comprising an mRNA encapsulated in a lipid nanoparticle (LNP), wherein the mRNA comprises a first coding region and a second coding region separated by a 2A-like sequence, wherein the first coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS) and the second coding region is a coding region of an antigen or the first coding region is a coding region of an antigen and the second coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

4. The composition of any one of embodiments 1-3, wherein the at least one lipid comprises an ionizable lipid, a pegylated lipid, and a structural lipid.

5. The composition of any one of embodiments 1-4, wherein the ionizable lipid comprises:

i) 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester (SM-102) or analogs or derivatives thereof; and/or

ii) 6-((2-hexyldecanoyl)oxy)-N-(6-((2-hexyldecanoyl)oxy)hexyl)-N-(4-hydroxybutyl)hexan-1-aminium (ALC-0315) or analogs or derivatives thereof; and/or

iii) (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA)ALC-0315 or analogs or derivatives thereof.

6. The composition of any one of embodiments 1-5, wherein the pegylated lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatide acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and combinations thereof.

7. The composition of any one of embodiments 1-5, wherein the pegylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG].

8. The composition of any one of embodiments 1-7, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and combinations thereof.

9. The composition of any one of embodiments 1-7, wherein the structural lipid comprises cholesterol.

10. The composition of any one of embodiments 1-9, wherein the phospholipid comprises:

i) a hydrophilic head moiety selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2-lysophosphatidyl choline, and sphingomyelin; and

ii) one or more fatty acid tail moieties selected from the group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, arachidic acid, arachidonic acid, phytanoic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.

11. The composition of any one of embodiments 1-9, wherein the phospholipid is selected from the group consisting of:

1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),

1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine,
 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine,
 1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
 1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
 1,2-didocosaheptaenoyl-sn-glycero-3-phosphocholine,
 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine,
 1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
 1,2-dilinoeloyl-sn-glycero-3-phosphoethanolamine,
 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
 1,2-didocosaheptaenoyl-sn-glycero-3-phosphoethanolamine,
 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG),
 sphingomyelin, and
 combinations thereof.

12. The composition of embodiment 11, wherein the phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

13. The composition of any one of embodiments 1-12, wherein the composition further comprises at least one excipient, optionally wherein the excipient comprises sucrose.

14. The composition of any one of embodiments 1-13, wherein the composition does not comprise a lysophosphatidylcholine (LPC), optionally wherein the LPC has a single C13-C24 acyl chain.

15. A composition comprising:
an mRNA complexed with one or more lipids (RNA-Lipoplex); and
wherein the mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the one or more lipids comprise a first lipid and a second lipid.

16. A composition comprising:
a first mRNA and a second mRNA complexed with one or more lipids (RNA-Lipoplex); and
wherein the first mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the second mRNA comprises a coding region of an antigen, and the one or more lipids comprise a first lipid and a second lipid.

17. A composition comprising:
an mRNA complexed with one or more lipids (RNA-Lipoplex); and
wherein the mRNA comprises a first coding region and a second coding region separated by a 2A-like sequence, the first coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS) and the second coding region is a coding region of an antigen or the first coding region is a coding region of an antigen and the second coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the one or more lipids comprise a first lipid and a second lipid.

18. The composition of any one of embodiments 15-17, wherein the first lipid is a cationic lipid, and the second lipid is a neutral or anionic lipid.

19. The composition of embodiment 18, wherein the cationic lipid comprises one or both of:

i) 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) or analogs or derivatives thereof; and

ii) 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) or analogs or derivatives thereof.

20. The composition of embodiment 18 or embodiment 19, wherein the neutral or anionic lipid comprises:

i) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) or analogs or derivatives thereof; and/or

- ii) cholesterol or analogs or derivatives thereof; and/or
- iii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or analogs or derivatives thereof.

21. The composition of any one of embodiments 1-20, further comprising a TLR7/8 agonist.

22. The composition of embodiment 21, wherein the TLR7/8 agonist is a small molecule with a molecule weight of 900 daltons or less.

23. The composition of embodiment 22, wherein the TLR7/8 agonist comprises an imidazoquinoline compound.

24. The composition of embodiment 23, wherein the TLR7/8 agonist comprises resiquimod (R848).

25. The composition of any one of embodiments 1-24, wherein the mRNA or the first mRNA and the second mRNA comprises a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR).

26. The composition of any one of embodiments 1-25, wherein the mRNA comprises a 5' cap structure.

27. The composition of any one of embodiments 1-26, wherein the mRNA comprises a polyA tail.

28. The composition of any one of embodiments 1-27, wherein the mRNA is a nucleoside-modified mRNA.

29. The composition of any one of embodiments 1-28, wherein the constitutively-active cGAS has a greater propensity to self DNA reactivity than its wild-type counterpart.

30. The composition of any one of embodiments 1-29, wherein the cGAS is a truncated cGAS devoid of an amino-terminal phosphoinositide-binding domain (cGAS Δ N).

31. The composition of embodiment 30, wherein the cGAS Δ N comprises the amino acid sequence of SEQ ID NO:1 or the amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1.

32. The composition of embodiment 31, wherein the cGASΔN comprises:
- (i) the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, or the amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8; or
 - (ii) the consensus amino acid sequence of SEQ ID NO:9.
33. The composition of embodiment 31, wherein the cGASΔN is encoded by the nucleotide sequence of SEQ ID NO:17.
34. The composition of any one of embodiments 30-33, wherein the coding region of the cGASΔN is in operable combination with a start codon (ATG).
35. The composition of any one of embodiments 1-34, wherein the antigen is a tumor antigen.
36. The composition of embodiment 35, wherein the tumor antigen is a tumor-associated antigen.
37. The composition of embodiment 35, wherein the tumor antigen is a neoantigen.
38. The composition of any one of embodiments 1-34, wherein the antigen comprises a microbial antigen.
39. The composition of embodiment 38, wherein the microbial antigen comprises a viral antigen, a bacterial antigen, a protozoan antigen, or a fungal antigen.
40. The composition of any one of embodiments 1-34, wherein the antigen comprises a surface protein or fragment thereof of a pathogen.
41. The composition of embodiment 40, wherein the pathogen is capable of causing disease in human subjects.
42. The composition of embodiment 40 or embodiment 41, wherein the pathogen is a virus.
43. The composition of embodiment 42, wherein the virus is a SARS-CoV-2.

44. The composition of embodiment 43, wherein the antigen is a spike (S) glycoprotein of the SARS-CoV-2, optionally wherein the spike glycoprotein is a pre-fusion stabilized variant.

45. The composition of any one of embodiments 1-44, wherein the composition does not comprise lipopolysaccharide (LPS) or monophosphoryl lipid A (MPLA).

46. The composition of any one of embodiments 1-45, wherein the composition does not comprise oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC) or a species of oxPAPC.

47. The composition of embodiment 46, wherein the composition does not comprise 2-[[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium(HOdiA-PC), [(2R)-2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-hexadecanoyloxypropyl] 2- (trimethylazaniumyl)ethyl phosphate (KODiA-PC), 1-palmitoyl-2-(5-hydroxy-8-oxo-octenoyl)-sn-glycero-3-phosphorylcholine (HOOA-PC), 2-[[[(2R)-2-[(E)-5,8-dioxooct-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium (KOOA-PC), [(2R)-3-hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2- (trimethylazaniumyl)ethyl phosphate (POVPC), [(2R)-2-(4-carboxybutanoyloxy)-3-hexadecanoyloxy propyl] 2- (trimethylazaniumyl)ethyl phosphate (PGPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[2-[(Z)-oct-2-enyl]-5-oxocyclopent-3-en-1-ylidene]methyl]oxiran-2-yl]butanoyloxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate (PECPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[3-hydroxy-2-[(Z)-oct-2-enyl]-5-oxocyclopentylidene]methyl]oxiran-2-yl]butanoyloxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate (PEIPC) and/or 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC).

48. A pharmaceutical formulation comprising the composition of any one of embodiments 1-47, and a pharmaceutically acceptable excipient.

49. A method for production of hyperactivated dendritic cells, the method comprising contacting the dendritic cells with an effective amount of the composition of any one of embodiments 1-47, any one of embodiments 21-47, or the formulation of embodiment 48 to produce hyperactivated dendritic cells, wherein the hyperactivated dendritic cells secrete IL-1beta without undergoing cell death within about 48 hours of exposure.

50. The method of embodiment 49, wherein the dendritic cells are:

- (i) contacted in vivo with the composition; or
- (ii) contacted ex vivo with the composition.

51. The method of embodiment 49 or embodiment 50, wherein the hyperactivated dendritic cells:

- (i) secrete higher levels of one or more of RANTES, IP-10 and IFN α than unstimulated dendritic cells or dendritic cells contacted with empty LNPs; and/or
- (ii) express higher levels of at least one cell surface marker selected from the group consisting of CD40, CD86, CD69, MHC class II, MHC class I, CCR7, and combinations thereof.

52. A pharmaceutical formulation comprising at least 10^3 , 10^4 , 10^5 or 10^6 of the hyperactivated dendritic cells produced by the method of any one of embodiments 49-51, and a pharmaceutically acceptable excipient.

53. A method of stimulating an immune response against an antigen, comprising administering an effective amount of the pharmaceutical formulation of embodiment 48 or embodiment 52 to an individual in need thereof to stimulate the immune response against the antigen.

54. A method of treating cancer, comprising administering an effective amount of the pharmaceutical formulation of embodiment 48 or embodiment 52 to an individual in need thereof to treat the cancer.

55. A method of inhibiting abnormal cell proliferation, comprising administering an effective amount of the pharmaceutical formulation of embodiment 48 or embodiment 52 to an individual in need thereof to inhibit abnormal cell proliferation.

56. A method of treating or preventing an infectious disease, comprising administering an effective amount of the pharmaceutical formulation of embodiment 48 to an individual in need thereof to treat or prevent the infectious disease.

57. The method of embodiment 56, wherein the infectious disease is a viral disease.

58. The method of embodiment 56, wherein the infectious disease is a bacterial disease.

59. The method or pharmaceutical formulation of any one of embodiments 49-55, wherein the dendritic cells are mammalian cells.

60. The method or pharmaceutical formulation of embodiment 59, wherein the mammalian cells are human cells.

61. The method of any one of embodiments 53-59, wherein the individual is mammal.

62. The method of embodiment 61, wherein the mammal is a human.

63. The method of embodiment 61, wherein the mammal is a dog or a cat.

64. The composition, formulation, or method of any one of embodiments 1-63, wherein the phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and the least one lipid comprises 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester (SM-102) or analogs or derivatives thereof, and cholesterol.

65. The composition, formulation, or method of embodiment 64, wherein the at least one lipid further comprises a pegylated lipid, optionally wherein the pegylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG].

66. The composition, formulation, or method of any one of embodiments 1-65, wherein the LNP has an effective diameter of less than about 250 nanometers, optionally from about 25 to about 250 nanometers, optionally from about 50 to about 200 nanometers, or optionally from about 75 to about 175 nanometers.

67. The composition, formulation, or method of embodiment 66, wherein the LNP has an effective diameter of less than about 200 nanometers.

68. The composition, formulation, or method of claim 67, wherein the LNP has an effective diameter of less than about 150 nanometers.

EXAMPLES

[0088] Abbreviations: BMDC (bone marrow-derived dendritic cell); CDS (cytosolic DNA sensor); cyclic GMP-AMP synthase (cGAS); CLR (C-type lectin receptor); DAMP (damage-associated molecular pattern); DC (dendritic cell); dLN (draining lymph node); DLS (dynamic light scattering); DMG-PEG-2000 (polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG]); DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine); ELSD (evaporative light scattering detector); FLT3L (Fms-related tyrosine kinase 3 ligand); GFP (green fluorescent protein); GV (GenVoy ILM™ formulation); (HOdiA-PC (1-palmitoyl-2-(5-hydroxy-8-oxo-6-octenedioyl)-sn-glycero-3-phosphatidylcholine); HOOA-PC (1-palmitoyl-2-(5-hydroxy-8-oxooct-6-enoyl)-sn-glycero-3-phosphocholine); IFN γ (interferon-gamma); IL-1b/IL-1 β (Interleukin-1 β); KOdiA-PC (1-(palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine); KOOA-PC (1-palmitoyl-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine); LNP (lipid nanoparticle); LPC/Lyso PC (lysophosphatidylcholine); Lyso PC(22:0) (1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine); LPS (lipopolysaccharide); MC3 ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, also referred to as DLin-MC3-DMA); mcg or μ g (microgram); moDC (monocyte-derived dendritic cell); MPLA (monophosphoryl lipid A); NLR (NOD-like receptor); OVA (ovalbumin); oxPAPC (oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine); PAMP (pathogen-associated molecular pattern); PBMCs (peripheral blood mononuclear cells); PGPC (1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine); POVPC (1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine); PRR (pathogen recognition receptor); RLR (RIG-I-like receptor); R848 (resiquimod); SC (subcutaneously); STING (stimulator of interferon genes); TNF α (tumor necrosis factor-alpha); and TLR (toll-like receptor).

[0089] Although the present disclosure has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the following examples should not be construed as limiting the scope of the present disclosure, which is delineated by the appended claims.

Example 1: Murine DCs Are Activatable In Vitro By LNPs Containing cGASΔN mRNA**Materials & Methods**

[0090] *Materials.* GenVoy ILM™ ionizable lipid mixture was purchased from Precision Nanosystems. CleanCap OVA and GFP mRNAs were purchased off-the-shelf from Trilink, with a 120 residue polyA tail, a 5-methoxyuridine base modification, and codon optimization for expression in mammalian systems. cGASΔN mRNA was custom ordered from Trilink and was synthesized via in vitro transcription from linearized template DNA. The nucleotide sequence of human cGASΔN sequence was codon optimized for expression in murine cells, and the synthetic nucleotide sequence is set forth as SEQ ID NO:17. The mRNA sequence was capped using Trilink's proprietary Clean Cap mRNA technology, with a N1-methylpseudouridine base modification, and a 120 residue polyA tail. The sequence contains a BbsI restriction enzyme site. The mRNA was phosphatase treated after synthesis.

[0091] *LNP Synthesis.* Lipid nanoparticles (LNPs) were prepared using the GenVoy ILM™ ionizable lipid mixture (Precision Nanosystems). OVA mRNA, GFP mRNA, and cGASΔN mRNA (Trilink), were each prepared at 0.17 mg/mL in sodium citrate buffer, pH 4. GenVoy ILM™ was used at 12.5 mM. LNPs were synthesized using the NanoAssemblr Ignite instrument (Precision Nanosystems). Lipids in ethanol were combined with the mRNA solutions individually at a 1:3 volumetric ratio, using a flow rate of 12 mL/min. LNPs were washed in 10 volumes of phosphate buffered saline (PBS), pH 7.4 to remove residual ethanol, and then concentrated using Amicon 10K MWCO centrifugal filters. LNPs were filtered through a 0.2 μm filter before use.

[0092] *LNP Characterization.* Loading of mRNA into LNPs was quantified using a RiboGreen assay (ThermoFisher) following the manufacturer's protocol. Samples were diluted to fall within the range of the standard curve. LNPs were lysed using Triton X-100 to assess encapsulation of mRNA into LNPs. Both total mRNA and encapsulated mRNA were quantified. The size of the LNPs was assessed using dynamic light scattering (DLS) on the NanoBrook Omni (Brookhaven). LNPs were diluted 1:10 in PBS before running on the DLS. Three 90 second measurements were recorded for each sample.

[0093] *Murine bone marrow-derived FLT3L-DCs generation.* Leg femur and tibia were removed from mice, cut with scissors, and flushed into sterile tubes. Bone marrow suspension was treated with ACK Lysis Buffer for 1 minute, then passed through a 40 μ m cell strainer. Cells were counted and resuspended in media consisting of complete IMDM containing 10% FBS, penicillin and streptomycin, and supplements of L-glutamine and sodium pyruvate (I10). Cells were then plated at 8×10^6 bone marrow cells per well in a P12 plate. Recombinant mouse FLT3L (Miltenyi) was added to cultures at 200 ng/mL. Differentiated cells were used for subsequent assays on day 8. The efficiency of differentiation was monitored by flow cytometry using a BD Symphony A3, and CD11c⁺MHC-II⁺ cells were routinely above 80% of living cells. For each experiment, 5 to 15 mice were used to generate DCs from bone marrow.

[0094] *Murine FLT3L-DCs stimulation.* FLT3L-DCs were harvested 8 days post differentiation, counted and the treated with lipid nanoparticles (LNPs) based on the mRNA content. Cells were treated with 1 μ g/mL mRNA in 200 μ L total media/well. About 24 hours post incubation, cells and culture supernatant were used for downstream readouts. 150 μ L of cell supernatant from each well was collected to measure cytokine secretion from DC. LEGENDplex™ Mouse Anti-Virus Response Panel (Biolegend) was used according to the manufacturer's protocol. Data were collected using a BD FACS Symphony and analyzed using the cloud-based software provided by Biolegend. To assess DC activation post LNP exposure, FLT3L DCs were collected 24 hours after LNP addition and stained to measure the expression of the following cell surface markers: CD11c, MHC-II, CD24, SIRP1a, CD40, CD86, CD69, and H2kb (MHC-I). Graphs show means and SD of triplicates. Data are representative of two experiments.

Results

[0095] *LNPs loaded with mRNA encoding cGASΔN (cGASΔN LNPs) exhibit similar sizing and loading profiles to LNPs loaded with mRNA encoding model antigens.* cGASΔN mRNA loaded LNPs showed similar size and mRNA loading profiles to the LNPs loaded with model antigen mRNAs – OVA and GFP. All mRNA-loaded LNPs had an average effective diameter less than 150 nm (**FIG. 3A**), with a relatively uniform size profile, exhibited by polydispersity indexes less than 0.3 (**FIG. 3B**). All mRNAs loaded into the GenVoy ILM LNPs

with the measured mRNA loading showing 90-110% of the theoretically loaded amount of mRNA (**FIG. 3C**).

[0096] *cGASΔN LNPs induce IFN-I-dependent response in murine DCs.* FLT3L DCs were stimulated with empty LNPs (no mRNA), or LNPs containing either GFP mRNA or OVA mRNA or cGASΔN mRNA alone. Alternatively, DCs were stimulated with LNPs containing OVA mRNA plus empty LNPs or OVA mRNA plus LNPs containing cGASΔN or LNPs containing cGASΔN plus LNPs containing GFP mRNA. LNPs were added to cell cultures based on the concentration of mRNA at 1 μg/mL. 24 hours post stimulation, cell supernatants were measured for the presence of cytokines using a multiplexed cytokine bead array Legendplex assay. Interestingly, we found that upon cGASΔN LNP treatment, BMDCs secreted RANTES, IP-10, and IFNα at significantly higher levels than when treated with mRNA antigen-loaded LNPs alone (**FIG. 4A, FIG. 4B, FIG. 4C**). These data indicated that constitutively active cGASΔN is successfully expressed and is functional in mouse DCs. Pro-inflammatory cytokines dependent on NFκB were not secreted, including IL-6 and TNFα, suggesting that constitutively active cGASΔN induce NFκB activation in specific cell types. We compared the induction of these cytokine upon LNPs treatment to stimulation with LPS and R848 PAMPs. Interestingly IP-10, RANTES, and IFNα were expressed either more strongly or at similar levels by cGASΔN LNP treatment as compared to higher doses of LPS or R848 suggesting that the IRF3 pathway can be strongly induced by the expression of constitutively active cGASΔN.

[0097] *cGASΔN LNPs induce murine DCs activation.* To assess DC activation, LNP-treated DCs were stained 24 hours following treatment with activation markers on total cDC as well as cDC1 and cDC2 subsets of DCs. The expression of T cell costimulatory surface molecules CD40, CD86 and CD69 increased when cells were treated with cGASΔN LNP but not with empty LNPs or GFP LNPs or OVA containing LNPs (**FIG. 5A, FIG. 5B, FIG. 5C**) when assessed by median fluorescence intensity (MFI). This trend also held true for cDC1 subsets. In addition, MHCII and H2kB antigen presentation molecules were increased on cDCs when they were treated with cGASΔN LNPs compared to standard mRNA antigen LNPs (**FIG. 5D, 5E**). This also held true for cDC1 subsets. Further, CCR7 surface expression, indicative of the potential for DCs to migrate to LN, was increased on cDCs when they were treated with

cGASΔN LNPs compared to standard mRNA antigen LNPs (**FIG. 5F**). This trend was also true for cDC1 subsets. Overall, these data indicate that cGASΔN LNPs induce cGAS-STING pathway activation within DCs leading to a DC activation state and production of type-I IFN.

Example 2: Human Cells Are Activatable Into An Inflammatory State In Vitro By LNPs Containing cGASΔN mRNA

Materials & Methods

[0098] *Materials.* Lipids for LNPs were purchased from Cayman Chemicals (SM102) or Avanti (22:0 LPC, DSPC, DMG-PEG2000). Cholesterol was purchased from Sigma. GenVoy ILM lipids were purchased from Precision Nanosystems. CleanCap OVA and GFP mRNA were purchased off-the-shelf from Trilink, with a 120 polyA tail and base modification 5-methoxyuridine, optimized for mammalian systems. cGASΔN mRNA was custom ordered and synthesized via in vitro transcription from a linearized template DNA (Trilink). The human cGASΔN sequence was codon optimized to be expressed in mouse. The sequence was capped using Trilink's proprietary Clean Cap mRNA technology, with base modification N1-methylpseudouridine and a 120 polyA tail. The sequence contains a BbsI restriction enzyme site. The sequence information was used to build plasmids, from which the mRNA was synthetically synthesized. mRNA was phosphatase treated after synthesis.

[0099] *LNP Synthesis.* Lipid nanoparticles (LNPs) were prepared using the GenVoy ILM LNP lipid mix (Precision Nanosystems) or a custom LNP lipid mix (**Table 2-1**). OVA mRNA, GFP mRNA, and cGASΔN mRNA (Trilink), were each prepared at 0.17 mg/mL in sodium citrate buffer, pH 4. GenVoy ILM and the custom LNP lipid mix were used at 12.5 mM. LNPs were synthesized using the NanoAssemblr Ignite instrument (Precision Nanosystems). Lipids in ethanol were combined with the mRNA solutions individually at a 1:3 volumetric ratio, using a flow rate of 12 mL/min. LNPs were washed in 10 volumes of phosphate buffered saline (PBS), pH 7.4 to remove residual ethanol, and then concentrated using Amicon 10K MWCO centrifugal filters. LNPs were filtered through a 0.2 μm filter before use.

Table 2-1. LNP Formulations

Lipid	GenVoy ILM™	Custom Lipid Mix
Ionizable Lipid	Proprietary Lipid 50%	SM102 40%
DSPC	10%	35%
Cholesterol	37.5%	28.5%
Stabilizer Lipid	Proprietary Lipid 2.5%	DMG-PEG2000 1.5%

[0100] *LNP Characterization.* Loading of mRNA into LNPs was quantified using a RiboGreen assay (ThermoFisher) following the manufacturer's protocol. Samples were diluted to fall within the range of the standard curve. LNPs were lysed using Triton X-100 to assess encapsulation of mRNA into LNPs. Both total mRNA and encapsulated mRNA were quantified. The size of the LNPs was assessed using dynamic light scattering (DLS) on the NanoBrook Omni (Brookhaven). LNPs were diluted 1:10 in PBS before running on the DLS. Three 90 second measurements were recorded for each sample.

[0101] *Human monocyte derived dendritic cells (moDC) generation.* Human monocytes were isolated from Leukopaks purchased from Miltenyi using the StraightFrom Leukopak CD14 microbead kit (Miltenyi). Isolations were completed following manufacturer's instructions. Monocytes were then aliquoted and frozen in fetal bovine serum containing 10% dimethyl sulfoxide. For studies with monocyte-derived dendritic cell (moDC) cultures, monocytes were thawed and cultured in RPMI medium containing 10% FBS, 50 units/mL penicillin, 50 mg/mL streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 mM beta-mercaptoethanol, 10mM HEPES, and Gibco MEM non-essential amino acids (R10 media). To differentiate monocytes into moDCs, recombinant human GM-CSF (50 ng/mL) and IL-4 (25 ng/mL) were added to R10 media. Cells were cultured for 6 days with GM-CSF and IL-4, with an additional cell feeding with R10 media containing GM-CSF and IL-4 on day 3. Six days after differentiation, moDC were collected and counted. Cells were plated into 96-well flat-bottom plates at 1E5 cells/well in R10 media.

[0102] *THP-1 cell generation.* THP1-Null2 (Invivogen) cells were thawed into and maintained in RPMI medium containing 10% heat-inactivated FBS, 25mM HEPES, 100U/mL penicillin/streptomycin, 100µg/mL normocin, and supplemented with 100µg/mL zeocin every

other passage. Cells were passaged between $0.4\text{--}0.6 \times 10^6$ cells/mL in T75 culture flasks, with two cell passages per week. Cells are maintained until passage 20, after which a new vial was thawed. Before treating with LNPs, THP1-Null2 cells were collected from flasks and plated in RPMI medium containing 10% heat-inactivated FBS, 25mM HEPES, and 100U/mL penicillin/streptomycin at 100,000 cells/well in 96-well flat-bottom tissue culture plates.

[0103] *Human cell activations.* THP-1 cells and moDC were treated with lipid nanoparticles (LNPs) based on the concentration of mRNA content. Cells were treated with 0.2 $\mu\text{g/mL}$ mRNA delivered in LNPs in a total stimuli volume of 200 $\mu\text{L/well}$. After an overnight incubation, cells and culture supernatant were used for downstream readouts. One hundred and fifty microliters of cell supernatant were collected. One day after LNP addition, cells and supernatant from THP-1 cultures were collected to measure IL-6 (Lumit assay by Promega) and IP-10 (ELISA kit from Biolegend) cytokines. THP-1 cells were used for staining activation markers for flow cytometry analysis. To measure cytokine secretion from moDC, the LegendPlex Anti-virus Response Panel (Biolegend) was used according to the manufacturer's protocol. Data were collected using a BD FACS Symphony and analyzed using the cloud-based software provided by Biolegend. Both moDC and THP-1 cells were collected 1 day after LNP addition and stained to measure the expression of the following cell surface activation markers: CD11c, CD209, CD40, CD80, CD83, CD86, HLA-ABC, and HLA-DR. Study was performed on two different human donor samples and on THP-1 cells, and each biological condition was tested in triplicate. Graphs show data from two human samples or THP-1 cells. Data is representative of two experiments.

[0104] *HEK-Blue IL-1 β Reporter Assay.* moDC were treated with lipid nanoparticles (LNPs) based on the concentration of mRNA content. Cells were treated with 1 $\mu\text{g/mL}$ OVA mRNA, 1 $\mu\text{g/mL}$ cGAS ΔN mRNA, or 0.2 $\mu\text{g/mL}$ mRNA delivered in LNPs in a total stimuli volume of 200 $\mu\text{L/well}$. LNPs were delivered with media, R848, or R848 + MCC950, an inhibitor of NLRP3 inflammasomes. In the presence of MCC950, IL-1 β should not be secreted in an inflammasome dependent manner. HEK-Blue IL-1 β Reporter cells (Invivogen) were used to assess functional IL-1 β secreted by human moDCs in response to treatment with cGAS ΔN LNPs for 48 hours. HEK-Blue IL-1 β Reporter cells are derived from HEK293 cells, and express

an NK-kB/AP-1 inducible SEAP (secreted embryonic alkaline phosphatase) reporter that triggers SEAP production once the IL-1 β receptor encounters mature IL-1 β . SEAP production is monitored by a color change using the QUANTI-Blue solution. HEK-Blue IL-1 β Reporter cells were thawed into and maintained in DMEM medium containing 10% heat-inactivated FBS, 2mM L-glutamine, 100U/mL penicillin, 100 μ g/mL streptomycin, 100 μ g/mL normocin, and supplemented with 100 μ g/mL zeocin every other passage. Cells were passaged between 0.4-0.6X10⁶cells/mL in T75 culture flasks, with 2 cell passages per week. Cells are maintained until passage 20, after which a new vial is thawed. Before treating with LNPs, HEK-Blue IL-1 β Reporter cells were collected from flasks and plated in DMEM medium containing 10% heat-inactivated FBS, 2 mM L-glutamine, 100U/mL penicillin, and 100 μ g/mL streptomycin at 50,000 cells/well in 96-well flat-bottom tissue culture plates. 50 μ L of media from cGAS Δ N activated moDCs, or 50 μ L of media containing known concentrations of recombinant human IL-1 β to make a standard curve were added to wells containing HEK-Blue IL-1 β Reporter cells. Cells were incubated overnight, after which 20 μ L of SEAP-containing supernatant from incubated samples was mixed with 180 μ L of QUANTI-Blue solution. This reaction ran for 1 hour at 37C, after which absorbance at 630 nm was measured by spectrophotometry.

Results

[0105] To determine if cGAS Δ N LNPs would allow for greater cell activation than standard LNPs, LNPs were synthesized to contain mRNA encoding Ova antigen or mRNA encoding constitutively active cGAS Δ N. As experimental controls, LNPs were made with mRNA encoding GFP. These LNPs were tested individually or in combination on THP-1 cells (a human myeloid cell line) and primary human moDC. Two lipid formulations: GenVoy (Precision Nanosystems) and a custom lipid mix were included to determine if activity was LNP-formulation dependent. LNPs were added to cell cultures based on the concentration of mRNA at 0.2 μ g/mL.

[0106] *cGAS Δ N LNPs exhibit similar sizing and loading profiles to LNPs loaded with model antigens.* cGAS Δ N mRNA loaded LNPs showed similar size and mRNA loading profiles to the LNPs loaded with model antigen mRNAs – OVA and GFP. All mRNA-loaded LNPs had an average effective diameter less than 150 nm (**FIG. 6A**), with a relatively uniform size profile,

exhibited by polydispersity indexes less than 0.3 (**FIG. 6B**). All mRNAs loaded into the GenVoy ILM LNPs with 70-90% of the theoretically loaded amount of mRNA encapsulated in the LNPs (**FIG. 6C**). Both the GenVoy and the custom lipid mix allowed for LNP production, with similar sizing, although the optimized GenVoy formulation exhibited increased uniformity of size (**FIG. 6B**) as shown by a lower polydispersity index. Both the GenVoy and the custom lipid mix allowed for similar loading levels for all mRNAs, with the GenVoy formulation encapsulating the mRNA slightly more efficiently.

[0107] *cGASΔN LNPs activate inflammatory pathways in human moDC.* Frozen monocytes from two donors were thawed and differentiated into moDC using GM-CSF and IL-4. The cells were treated with LNPs at an mRNA loading of 0.2 μg/mL. Using a multiplexed cytokine bead array assay, multiple inflammatory cytokines were found to be upregulated. Upon cGASΔN LNP treatment, IL-6 (**FIG. 7A**), TNFα (**FIG. 7B**), IP-10 (**FIG. 7C**), IFN λ1 (**FIG. 7D**), IFNβ (**FIG. 7E**), and IFNα2 (**FIG. 7F**) were detectable at an elevated level within one day compared to treatment with LNPs loaded with model antigen. The expression of IL-6 suggested that constitutively active cGAS can induce NF-kB activation and is maybe cell type dependent. Interestingly IP-10, IFNλ1, and IFNβ were expressed more strongly by cGASΔN LNP treatment than when cells were treated with 10 μg/mL LPS, which served as a positive control, suggesting that the IRF3 pathway can be strongly induced by the expression of constitutively active cGAS.

[0108] LNP-treated moDC were stained 1 day following treatment to quantify expression of activation markers. By measuring the median fluorescence intensity (MFI), CD83 expression increased when cells were treated with cGASΔN LNP compared to standard LNPs (**FIG. 8A**). Expression of T cell costimulatory molecules were also measured. CD40, CD80 expression increased in the overall population of moDC and also at the single cell level when they were treated with cGASΔN LNPs (**FIG. 8B, FIG. 8C**). While HLA-DR was expressed by nearly all moDC, MFI measurements revealed that MHC Class II molecules were increased on individual cells when moDC were treated with cGASΔN LNPs (**FIG. 8D**). In the case of MHC Class I molecules, HLA-ABC staining did not reveal any cGASΔN LNP-dependent changes.

[0109] *cGASΔN LNPs activate inflammatory pathways in THP-1.* After one day of incubation, THP-1 cell supernatants were measured for the presence of cytokines that are

dependent upon NF- κ B or IRF3 activation, IL-6 and IP-10 respectively. At both time points, IL-6 was not differentially expressed by THP-1 cells treated with cGAS LNPs, suggesting that NF- κ B is not activated. In contrast, IP-10, a gene controlled by IRF3, was expressed within a day of cGAS LNP treatment (**FIG. 9A**). cGAS LNPs induced IP-10 expression whereas other control LNPs induced little to no IP-10. The detectable IP-10 indicated that packaging a transcript of constitutively active cGAS into an LNP can be a method to activate the innate immune system.

[0110] To further verify that cGAS LNPs activate innate immune signaling, the THP-1 cells were collected 1 day after the start of incubation to stain for cell surface expression of activation markers. THP-1 samples were gated on live, single-cell events. CD40 expression was observed to increase after cell treatment with cGAS LNPs whereas other control LNPs carrying GFP or Ova transcripts did not (**FIG. 9B**). CD40 is a receptor that augments the immune response via cell-cell interactions with its cognate ligand.

[0111] *Treatment with cGAS Δ N LNPs + R848 results in moDC hyperactivation.* moDCs were stimulated with R848 and cGAS Δ N to determine if the combination of NF- κ B stimulation and cGAS-STING pathway activation would allow for more potent inflammatory activity. Specifically, the moDC's ability to be hyperactivated by this combination was tested. Hyperactivation was typified by the DCs' ability to secrete IL-1 β while remaining viable. moDCs were either left unstimulated (PBS treated), or treated with cGAS Δ N LNPs or OVA LNPs in the presence of media, R848, or R848 and MCC950. MCC950 is an NLRP3 inflammasome inhibitor, so cells treated with MCC950 are not able to produce IL-1 β in an inflammasome dependent manner. Importantly, all cells treated with LNPs showed similar viability to moDCs treated with PBS alone, indicating that none of the cells were pyroptosing in response to LNP treatment (**FIG. 10A**). To determine if any active IL-1 β was produced by these cells in response to treatment with R848 and cGAS Δ N, supernatants from the moDC culture were added to HEK-Blue IL-1 β reporter cells that produce SEAP in response to IL-1 β . As expected, moDCs treated with PBS, R848, or R848 + MCC950 did not produce IL-1 β (**FIG. 10B**). To determine if hyperactivation was dependent on the LNP lipid composition, LNPs containing OVA were cultured with R848 – a condition which did not allow for IL-1 β production. Interestingly, LNPs loaded with cGAS Δ N, when delivered in combination with

R848, stimulated IL-1 β secretion in moDC (**FIG. 10B**). This response was NLRP3 inflammasome dependent, as treatment with MCC950 eliminated IL-1 β production.

[0112] Altogether, the data collected from treating THP-1 and human moDC with LNPs led to several conclusions. Firstly, the LNPs were successfully synthesized. Additionally, expression of constitutively active cGAS resulted in the upregulation of genes associated with the cGAS-STING pathway, in a formulation-independent manner. Inflammatory cytokines were expressed, and upregulation of activation markers were observed on the cell surface. Constitutively active cGAS encoded as mRNA and packaged in LNPs can be successfully utilized to initiate innate immune signaling in targeted cells to promote an inflammatory response. Lastly, constitutively active cGAS in combination with R848 allowed for moDC hyperactivation, with IL-1 β secretion occurring in live DCs.

Example 3: Murine Cells Are Activatable In Vivo By LNPs Containing cGAS Δ N mRNA

Materials & Methods

[0113] *Materials.* Lipids for LNPs were purchased from Cayman Chemicals (SM102) or Avanti (22:0 LPC, DSPC, DMG-PEG2000). Cholesterol was purchased from Sigma. GenVoy ILM lipids were purchased from Precision Nanosystems. CleanCap OVA and GFP mRNA were purchased off-the-shelf from Trilink, with a 120 polyA tail and base modification 5-methoxyuridine, optimized for mammalian systems. cGAS Δ N mRNA was custom ordered and synthesized via in vitro transcription from a linearized template DNA (Trilink). The human cGAS Δ N sequence was codon optimized to be expressed in mouse. The sequence was capped using Trilink's proprietary Clean Cap mRNA technology, with base modification N1-methylpseudouridine and a 120 polyA tail. The sequence contains a BbsI restriction enzyme site. The sequence information was used to build plasmids, from which mRNA was synthetically synthesized. mRNA was phosphatase treated after synthesis.

[0114] *LNP Synthesis.* Lipid nanoparticles (LNPs) were prepared as in Example 2 using the GenVoy ILM LNP lipid mix (Precision Nanosystems) or a typical LNP lipid mix (**Table 2-1**, Example 2). OVA mRNA, GFP mRNA, and cGAS Δ N mRNA (Trilink), were each prepared at 0.17 mg/mL in sodium citrate buffer, pH 4. GenVoy ILM and the typical LNP lipid mix were used at 12.5 mM. LNPs were synthesized using the NanoAssemblr Ignite instrument

(Precision Nanosystems). Lipids in ethanol were combined with the mRNA solutions individually at a 1:3 volumetric ratio, using a flow rate of 12 mL/min. LNPs were washed in 10 volumes of phosphate buffered saline (PBS), pH 7.4 to remove residual ethanol, and then concentrated using Amicon 10K MWCO centrifugal filters. LNPs were filtered through a 0.2 μ m filter before use.

[0115] *LNP Characterization.* Loading of mRNA into LNPs was quantified as in Example 2 using a RiboGreen assay (ThermoFisher) following the manufacturer's protocol. Samples were diluted to fall within the range of the standard curve. LNPs were lysed using Triton X-100 to assess encapsulation of mRNA into LNPs. Both total mRNA and encapsulated mRNA were quantified. The size of the LNPs was assessed using dynamic light scattering (DLS) on the NanoBrook Omni (Brookhaven). LNPs were diluted 1:10 in PBS before running on the DLS. Three 90 second measurements were recorded for each sample.

[0116] *In vivo immunization with LNPs containing cGAS Δ N mRNA and OVA antigen mRNA.* BL6 mice were immunized subcutaneously with LNPs following the table below (**Table 3-1**). Antigen was delivered using OVA mRNA-loaded LNPs, as well as LNPs containing either adjuvant cGAS Δ N mRNA or non-adjuvanting GFP mRNA. Mice were dosed with the mRNA doses indicated in the table. OVA mRNA dose was fixed at 5 μ g/mouse, while adjuvant mRNA varied from 1 μ g/mouse to 10 μ g/mouse. Mice (n = 5/group) were given a primary immunization on Day 0, with a boost immunization of the same doses on Day 7. 7 days post boost, blood was collected for antibody and T cell responses. Serum was collected from the blood using serum separation tubes, while blood for cellular analysis was collected using K2EDTA tubes. After blood collection, mice were euthanized and the draining lymph nodes and spleen were collected and processed to single cell suspension.

Table 3-1. LNPs used in in vivo assessment of T and B cell responses to cGASΔN LNPs

Group	mRNA encoding OVA	mRNA encoding GFP and/or cGASΔN	Formulation
1	None	None	PBS
2	None	GFP (5 μg/mouse) + cGASΔN (5 μg/mouse)	GV
3	OVA (5 μg/mouse)	GFP (1 μg/mouse)	GV
4	OVA (5 μg/mouse)	GFP (5 μg/mouse)	GV
5	OVA (5 μg/mouse)	cGASΔN (1 μg/mouse)	GV
6	OVA (5 μg/mouse)	cGASΔN (5 μg/mouse)	GV
7	OVA (5 μg/mouse)	GFP (5 μg/mouse)	Custom
8	OVA (5 μg/mouse)	cGASΔN (5 μg/mouse)	Custom

[0117] *OVA-specific T cell tetramer assessment.* OVA-specific T cells in the blood of mice receiving OVA LNP immunization were assessed 7 days post boost. CD8⁺ T cells specific for SIINFEKL (SEQ ID NO:16), an OVA MHC-I epitope, were quantified in the blood using a tetramer analysis. Briefly, red blood cells in the blood were lysed using an RBC lysis buffer, with lysis completed twice to completely remove any RBCs in the blood. Cells were washed, then stained for viability (Live/Dead), SIINFEKL-tetramer binding (MBL), and CD3, CD4, and CD8 expression. Cells were fixed with 4% paraformaldehyde, and counting beads were added before running to allow for a total cell count. Data were collected using a BD FACS Symphony and analyzed using Flowjo (BD).

[0118] *OVA-specific Antibody assessment.* OVA-specific antibodies in the serum of mice receiving OVA LNP immunization were assessed 7 days post boost. OVA-specific total IgG, IgG1, and IgG2b were assessed using ELISA. Briefly, ELISA plates were coated with 10 μg/mL Endofit Ovalbumin (Invivogen) overnight, then washed and blocked with 2% bovine serum albumin. Plates were washed again, and then serum was added to the plates at a 1:500 dilution, followed by 1:5 dilutions completed for a total of 7 serum dilutions tested. Samples were washed, then incubated with detection antibody specific for IgG, IgG1, or IgG2b conjugated to HRP (Southern Biotech), to detect total, Th2 or Th1 skewing OVA-specific antibodies respectively. Plates were washed, then incubated with TMB, and stop solution was added once color development was completed.

Results

[0119] To determine if cGASΔN LNPs would induce greater antigen specific T and B cell responses in vivo, mice were immunized with OVA LNPs in combination with cGASΔN LNPs or GFP LNPs (**Table 3-1**), at different doses of cGASΔN or GFP mRNA. Mice were immunized and then boosted after 1 week. Blood was collected for antibody and T cell tetramer analysis 1 week after the boost. Two lipid formulations: GenVoy (Precision Nanosystems) and a custom lipid mix were included to determine if activity was LNP-formulation dependent.

[0120] *cGASΔN LNPs exhibit similar sizing and loading profiles to LNPs loaded with model antigens.* cGASΔN mRNA loaded LNPs were prepared according to Example 2, with characterization following the trends shown in **FIG. 6A-6C**. All LNPs showed similar size and mRNA loading profiles to the LNPs loaded with model antigen mRNAs – OVA and GFP. All mRNA-loaded LNPs had an average effective diameter less than 150 nm, with a relatively uniform size profile, exhibited by polydispersity indexes less than 0.3. All mRNAs loaded into the GenVoy ILM LNPs with 70-90% of the theoretically loaded amount of mRNA encapsulated in the LNPs.

[0121] *Treatment with OVA LNPs and cGASΔN LNPs increases OVA-specific CD8+ T cells.* After two immunizations with OVA LNPs (5 μg mRNA/mouse) delivered with cGASΔN LNPs (1 or 5 μg mRNA/mouse) or control GFP LNPs (1 or 5 μg mRNA/mouse) (**Table 3-1**), OVA-specific T cell presence in the blood was analyzed. Blood was collected 7 days post-boost, processed to remove red blood cells, and then stained for Live/Dead, CD3, CD8, CD4, and SIINFEKL-tetramer reactivity (OVA-specific CD8+ T cell epitope set forth as SEQ ID NO:16). Frequency of SIINFEKL-specific cells among live CD8+ T cells was determined, as well as the total absolute number of SIINFEKL-specific CD8+ T cells collected in the blood. When mice were treated with the GenVoy LNPs – OVA LNPs (5 μg mRNA), with cGASΔN or GFP LNPs (1 or 5 μg mRNA), the frequency of SIINFEKL-specific (OVA-specific) CD8+ T cells significantly increased when cGASΔN mRNA was delivered in addition to OVA, compared to when GFP mRNA was delivered in addition to OVA (**FIG. 11A**). Mice that did not receive OVA LNPs did not have SIINFEKL-specific CD8+ T cells. This trend was not formulation specific, as mice that received OVA LNPs (5 μg mRNA) and cGASΔN (5 μg mRNA) prepared with the custom lipid mix had a significantly higher frequency of SIINFEKL-specific T cells in the blood than mice that received OVA LNPs + GFP LNPs (5 μg mRNA)

(**FIG. 11B**). This trend also held true for the absolute number of SIINFEKL-specific CD8⁺ T cells, when prepared with either the GenVoy (**FIG. 11C**) or custom lipid mix (**FIG. 11D**). Interestingly, lowering the dose of cGASΔN mRNA did not seem to have a big impact on the frequency of OVA-specific T cells, suggesting that small amounts of this cGASΔN mRNA, in combination with standard lipid preparations containing antigen mRNA may be sufficient to significantly boost an antigen-specific T cell response.

[0122] *Treatment with cGASΔN LNPs decreases Th2 specific OVA-specific antibodies without impacting Th1 specific IgG responses.* After two immunizations with OVA LNPs (5 μg mRNA/mouse) delivered with cGASΔN LNPs (1 or 5 μg mRNA/mouse) or control GFP LNPs (1 or 5 μg mRNA/mouse) (**Table 3-1**), OVA-specific antibodies in the blood were quantified. Blood was collected 7 days post-boost, serum was isolated, after which total IgG, IgG1 (associated with Th2 responses), and IgG2a (associated with Th1 responses), were analyzed. Traditionally, immunization with mRNA antigen loaded LNPs results in strong antibody responses, so antibody response was assessed to determine if the addition of cGASΔN LNPs in the treatment would reduce the expected response. Interestingly, mice treated with OVA and cGASΔN LNPs prepared using the GenVoy formulations did not show significant changes in OVA-specific total IgG measured compared to OVA + GFP LNP treatment (**FIG. 12A**). Mice that did not receive OVA LNPs did not produce OVA-specific antibodies. This was not a formulation specific response: OVA-specific total IgG measured was not significantly impacted by the presence cGASΔN in LNPs prepared using the custom lipid mix (**FIG. 12B**). OVA-specific IgG1 was also assessed, as IgG1 is typically associated with a Th2 immune responses. OVA-specific IgG1 was significantly reduced by the presence cGASΔN in LNPs prepared using GenVoy formulations ($p < 0.05$ for the 1:500 and 1:2500 dilution at both 1 ug and 5 ug cGASΔN vs GFP LNPs) (**FIG. 12C**). This reduced OVA-specific IgG1 responses was also measured in mice treated with cGASΔN LNPs prepared using the custom lipid mix ($p < 0.05$ for the 1:500, 1:2500, and 1:12500 dilution at 5 ug cGASΔN vs GFP LNPs) (**FIG. 12D**). IgG2a levels were also assessed, as IgG2a is associated with more strongly inflammatory Th1 responses. Importantly, mice treated with OVA and cGASΔN LNPs prepared using the GenVoy formulations (**FIG. 12E**) or the custom lipid mix (**FIG. 12F**) did not show significant changes in OVA-specific IgG2a compared to OVA + GFP treated mice.

[0123] Taken together, the data collected from the in vivo immunization experiment show that treating mice with cGASΔN LNPs in combination with antigen LNPs significantly improves antigen specific adaptive immune responses. Mice receiving cGASΔN LNPs showed significant increases in the number of antigen-specific T cells, without sacrificing antibody responses. In fact, the decrease in antigen-specific IgG1 without impacting the total antigen-specific IgG levels shows a skewing toward a Th1 associated immune response, which is beneficial in inducing protective immune responses (which are needed for immunotherapies). Combined, these data suggest that adding a low dose of cGASΔN LNPs to a standard antigen LNP preparation could result in much more potent immune responses to LNP vaccines.

SEQUENCES

SEQ ID NO:1

>HUMAN

PGASKLRVLEKLLSRDDISTAAGMVKGVDHLLRLKCDSAFRGVGLLN
TGSYYEHVKISAPNEFDVMFKLEVPRIQLEEYSNTRAYYFVKFKRNPKNPLSQFLEGEILSASKMLSKE
RKIIKEEINDIKDTDVIMKRKRGGSPAVTLLISEKISVDITLALESKSSWPASTQEGRLIQNWLSAKVRK
QLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGKSKTCCENKEEKCCRKDCLKLMKYLLLEQL
KERFKDKKHLDFSSYHVKTAFHFVCTQNPQDSQWDRKDLGLCFDNCVTYFLQCLRTEKLENYFIPEFNL
FSSNLIDKRSKEFLTKQIEYERNNEFPVFDEF

SEQ ID NO:2

>M. _MULATTA

PGARKLRVLEKLLRLSHQDISKAAKVNGVVGHLLRLKCEPEFGGVEQLH
TGSYYEHVKISAPNEFDVMFKLQVPRIQLEEYSDTGAYYFVKFKRNPKNPLSLFLEDEILSASKMLSKE
RKIIKEEINNIKDVQPDADVIMKRKRPGSPAVTLLINKEISVDITLALELKTSPASTQEGRLAIKNWLSA
KVRQQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILSNHGKSKTCCENKEMKCCRKDCLKLMKYLL
LEQLKEKFKDKKHLDFSSYHVKTAFHFLCTENPQDSQWDPKDLGLCFDNCVTYFLECLRTEQLKNYFIP
GFNLFSSNLIDKTSKEFLSKQIEYERNNEFPVFGEF

SEQ ID NO:3

>P. _ANUBIS

PGARKLRVLEKLLRLSHQDISKAAKVNGVVGHLLRLKCESEFEGVEQLH
TGSYYEHVKISAPNEFDVMFKLQVPRIQLEEYSDTGAYYFVKFKRNPKNPLSQFLEDEILSASKMLSQF
RKIIKEEINNIKDTDVIMKRKRGGSPAVTLLINKEISVDITLALELKTSPASTQEGRLAIKNWLSAKVRQ
QLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILSNHGKSKTCCENKEMKCCRKDCLKLMKYLLLEQL
KEKFKDKKHLDFSSYHVKTAFHFLCTENPQDSQWDPKDLGLCFDNCVTHFLQCLRTEKLANYFIPGFNL
FSSNLIDKSSKEFLSKQIEYERNNEFPVFGEF

SEQ ID NO:4

>N. _LEUCOGENYS

PGARKLRVLEKLLSRQEI SEAAEVNGVVDHLLRLQKCDSEFRGVGLLRRTGSYYEH

VKISAPNEFDVMFKLEVPRIQLEEYSNTGAYYFVKFKRNPKENPLSQFLEGEILSASKMLSFRKIIKEE
 INNIKDTDVIMKRKRGGSPAVTLLISEKISVDITLALESNSNSWPASTQEGLPIKDWLSGKVRRLKLP
 FYLVPHAKEGNGFQEETWRLSFSHIEKEILNNHGKTKTCCENKNVCCRKDCCLKMKYLLEQLKERFKD
 KKHLDKFSSYHVKTAFHHVCTENPQDSQWDPKNLGCDFDKCVIYFLKCLRTEQLGNYFIPGFNLFSNLI
 DKRSKEFLSKQIEYERNNEYPVFG

SEQ ID NO:5

>H_LAR

PGARKLPVLEKLKLSRQ

EICEAAEVVNGVVDHLLRRLQKCDSEFRGVGLLRTGSYYEHVKISAPNEFDVMFKLEVPRIQLEEYSNTG
 AYYFVKFKRNPKENPLCQFLEGEILSASKMLSFRKIIKEEINNIKDTDVILKRKRGGSPAVTLLISEKI
 SVDITLALESKSSSWPASTQEGLPIKDWLSGKVRTQLRLKPFYLVPHAKEGNGFQEETWRLSFSHIEKE
 ILNNHGETKTCCENKVKCCRKDCCLKMKYLLEQLKERFKDKKHLDKFSSYHVKTAFHHVCTENPKDSQW
 DPKDLGLCDFDKCVIYFLQCLSTEQLGNYFIPGFNLFSNLIIDKRSKEFLSKQIEYERNNEYPVFGKC

SEQ ID NO:6

>P._ABELII

PGASKLRVLEKLKLSRLEISKAAEVVNRVVDHLLRRLQKYNSEFRGVGLLRT

GSYYEHVKISAPNEFDVMFKLEVPRIQLEEYSNTGAYYFVKFKRNPKENPLSQFLEGEILSASKMLSFR
 KIIKEEINNIKDTDVIMKRKRGGSPAVTLLISEEISVDITLALESKSSWPASTQEGLPIKNWLSAKVRKQ
 LRLKPFYLVPHAKEGNGFQEETWRLSFSHIEKEILNNHGKSKTCCEDKEVKCCRKDCCLKMKYLLEQLK
 ERFKDKKHLDKFSSYHVKTAFHHVCTQNPQDSQWDPKDLGLCDFDNCVTYFLQCLRTEQLGNYFIPGFNLFS
 SSNLIIDKRSKEFLTKQIEYERNNEFPVFDEF

SEQ ID NO:7

>P._TROGLODYTES

PGASKLRVLEKLKLSRDDISTAAGMVKGVDHLLRLKCDSAFRGVGLLN

TGSYYEHVKISAPNEFDVMFKLEVPRIQLEEYSNTRAYYFVKFKRNPKENPLSQFLEGEILSASKMLSFR
 RKIIKEEINNIKDTDVIMKRKRGGSPAVTLLISEKISVDITLALESKSSWPASTQEGLPIKNWLSAKVRKQ
 RLKPFYLVPHAKEGNGFQEETWRLSFSHIEKEILNNHGKSKTCCCEIKEAKCCRKDCCLKMKYLLEQLKE
 KFKDKKHLDKFSSYHVKTAFHHVCTENPQDSQWDRKDLGLCDFDNCVTYFLQCLRTERLENYFIPEFNLS
 SLDIDKRSKEFLTKQIEYERNNEFPVFDEF

SEQ ID NO:8

>G._GORILLA

PGASKLRVLEKLKLSRDDISTAAGMVKGVDHLLRLKCDSAFRGVGLLN

TGSYYEHVKISAPNEFDVMFKLEVPRIQLEEYSNTRAYYFVKFKRNPKENPLSQFLEGEILSASKMLSFR
 RKIIKEEINNIKDTDVIMKRKRGGSPAVTLLISEKISVDITLALESKSSWPASTQEGLRIQNWLSAKVRR
 QLRLKPFYLVPHAKEGNGFQEETWRLSFSHIEKEILNNHGKSKTCCENKEAKCCRKDCCLKMKYLLEQL
 KERFKDKKHLDKFSSYHVKTAFHHVCTQNPQDSQWDRKDLGLCDFDNCVTYFLQCLRTERLENYFIPEFNLS
 FSRNLIIDKRSKEFLTKQIEYERNNEFPVFDEF

SEQ ID NO:9

>CGASΔN_CONSENSUS

PGAXKLXAVLEKLXLSXXXIXXAAXVXXVXXHLLXRLXXXXXXFXGVXXLX

TGSYYEHVKISAPNEFDVMFKLXVPRIQLEEYSXTXAYYFVKFKRNPXXNPLXXFLEXEILSASKMLSXF
 RKIIKEEINXIKXXXXXXDVIXKRKRXGSPAVTLLIXXXISVDITLALEXXXXSWPASTQEGLXIXXWLS
 XKVRXQLRLKPFYLVPHAKEGNGFQEETWRLSFSHIEKEILXNHGXKTCCEXKXXKCCRKDCCLKMKY
 LLEQLKEXFKDKKHLDKFSSYHVKTAFHXCTXNPXDSQWDXKXLGXCFDXCVTXFLXCLXXEXLXNYFI
 PXFNLSXXLIDKXSKEFLXKQIEYERNNEXPVFXXX

SEQ ID NO:10

>HUMANCGAS_FULL-LENGTH

MQPWHGKAMQRASEAGATAPKASARNARGAPMDPTESPAAPEAALPKAGKFGPARKSGSRQKKSAPDTQE
RPPVRATGARAKKAPQRAQDTQPSDATSAPGAEGLEPPAAREPALSRAGSCRQRGARCSTKPRPPPGPWD
VPSPGLPVSAPILVRRDAAPGASKLRVLEKLKLSRDDISTAAGMVKGVDHLLRLKCDSA FRGVGLLN
TGSYYEHVKISAPNEFDVMFKLEV PRIQLEEYSNTRAYYFVKFKRNPKENPLSQFLEGEILSASKMLS KF
RKIIKEEINDIKD TDVIMKRKRGGSPAVTLLISEKISVDITLALESKSSWPASTQEGLRIQNWLSAKVRK
QLRLKPFYLVPKHAKEGNFQEETWRLSF SHIEKEILNNHGKSKTCCENKEEKCCRKDCLKLMKYLLEQL
KERFKDKKHLDFSSYHVKTAF FHVCTQNPQDSQWDRKDLGLCFDNCVTYFLQCLRTEKLENYFIPEFNL
FSSNLIDKRSKEFLTKQIEYERNNEFPV FDEF

SEQ ID NO:11

>HUMANCGAS_N-TERMINUS

MQPWHGKAMQRASEAGATAPKASARNARGAPMDPTESPAAPEAALPKAGKFGPARKSGSRQKKSAPDTQE
RPPVRATGARAKKAPQRAQDTQPSDATSAPGAEGLEPPAAREPALSRAGSCRQRGARCSTKPRPPPGPWD
VPSPGLPVSAPILVRRDAA

SEQ ID NO:12

>THOSEA ASIGNA VIRUS T2A RIBOSOME-SKIPPING PEPTIDE

[GSG]EGRGSLLTCDGVEENPGP

SEQ ID NO:13

>PORCINE TESCHOVIRUS-1 P2A RIBOSOME-SKIPPING PEPTIDE

[GSG]ATNFSLLKQAGDVEENPGP

SEQ ID NO:14

>EQUINE RHINITIS A VIRUS E2A RIBOSOME-SKIPPING PEPTIDE

[GSG]QCTNYALLKLAGDVESNPGP

SEQ ID NO:15

>FOOT-AND-MOUTH DISEASE VIRUS F2A RIBOSOME-SKIPPING PEPTIDE

[GSG]VKQTLNFDLLKLAGDVESNPGP

SEQ ID NO:16

>GALLUS GALLUS OVALBUMIN PEPTIDE

SIINFEKL

SEQ ID NO:17

>SYNTHETIC CGAS Δ N

ATGCCCGGCCGAGCAAGCTGAGGGCCGTGCTGGAGAAGCTGAAGCTGAGCAGGGACGACATCA
GCACCGCCGCCGCGCATGGTGAAGGGCGTGGTGGACCACCTGCTGCTGAGGCTGAAGTGCGACAG
CGCCTTCAGGGGCGTGGGCCTGCTGAACACCGGCAGCTACTACGAGCACGTGAAGATCAGCGCC
CCCAACGAGTTCGACGTGATGTTCAAGCTGGAGGTGCCCAGGATCCAGCTGGAGGAGTACAGCA
ACACCAGGGCCTACTACTTCGTGAAGTTCAAGAGGAACCCCAAGGAGAACCCCTGAGCCAGTT
CCTGGAGGGCGAGATCCTGAGCGCCAGCAAGATGCTGAGCAAGTTCAGGAAGATCATCAAGGAG
GAGATCAACGACATCAAGGACACCGACGTGATCATGAAGAGGAAGAGGGGCGGCAGCCCCGCCG
TGACCCTGCTGATCAGCGAGAAGATCAGCGTGGACATCACCTGGCCCTGGAGAGCAAGAGCAG
CTGGCCCCGCCAGCACCCAGGAGGGCCTGAGGATCCAGAACTGGCTGAGCGCCAAGGTGAGGAAG

CAGCTGAGGCTGAAGCCCTTCTACCTGGTGCCCAAGCACGCCAAGGAGGGCAACGGCTTCCAGG
AGGAGACCTGGAGGCTGAGCTTCAGCCACATCGAGAAGGAGATCCTGAACAACCACGGCAAGAG
CAAGACCTGCTGCGAGAACAAGGAGGAGAAGTGCTGCAGGAAGGACTGCCTGAAGCTGATGAAG
TACCTGCTGGAGCAGCTGAAGGAGAGGTTCAAGGACAAGAAGCACCTGGACAAGTTCAGCAGCT
ACCACGTGAAGACCGCCTTCTTCCACGTGTGCACCCAGAACCCCCAGGACAGCCAGTGGGACAG
GAAGGACCTGGGCCTGTGCTTCGACAACCTGCGTGACCTACTTCCTGCAGTGCCTGAGGACCGAG
AAGCTGGAGAACTACTTCATCCCCGAGTTCAACCTGTTTCAGCAGCAACCTGATCGACAAGAGGA
GCAAGGAGTTCCTGACCAAGCAGATCGAGTACGAGAGGAACAACGAGTTCCCCGTGTTTCGACGA
GTTCTAATGA

CLAIMS

We claim:

1. A composition comprising an mRNA encapsulated in a lipid nanoparticle (LNP), wherein the mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

2. A composition comprising a first mRNA and a second mRNA encapsulated in a lipid nanoparticle (LNP), wherein the first mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), the second mRNA comprises a coding region of an antigen; and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

3. A composition comprising an mRNA encapsulated in a lipid nanoparticle (LNP), wherein the mRNA comprises a first coding region and a second coding region separated by a 2A-like sequence, wherein the first coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS) and the second coding region is a coding region of an antigen or the first coding region is a coding region of an antigen and the second coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the LNP comprises a phospholipid, and at least one lipid selected from the group consisting of an ionizable lipid, a pegylated lipid, a structural lipid, and mixtures thereof.

4. The composition of any one of claims 1-3, wherein the at least one lipid comprises an ionizable lipid, a pegylated lipid, and a structural lipid.

5. The composition of any one of claims 1-4, wherein the ionizable lipid comprises:
i) 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester (SM-102) or analogs or derivatives thereof; and/or
ii) 6-((2-hexyldecanoyl)oxy)-N-(6-((2-hexyldecanoyl)oxy)hexyl)-N-(4-hydroxybutyl)hexan-1-aminium (ALC-0315) or analogs or derivatives thereof; and/or

iii) (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA) or analogs or derivatives thereof.

6. The composition of any one of claims 1-5, wherein the pegylated lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatide acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and combinations thereof.

7. The composition of any one of claims 1-5, wherein the pegylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG].

8. The composition of any one of claims 1-7, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and combinations thereof.

9. The composition of any one of claims 1-7, wherein the structural lipid comprises cholesterol.

10. The composition of any one of claims 1-9, wherein the phospholipid comprises:

- i) a hydrophilic head moiety selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2-lysophosphatidyl choline, and sphingomyelin; and
- ii) one or more fatty acid tail moieties selected from the group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, arachidic acid, arachidonic acid, phytanoic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.

11. The composition of any one of claims 1-9, wherein the phospholipid is selected from the group consisting of

- 1,2-dilinoeoyl-sn-glycero-3-phosphocholine (DLPC),
- 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
- 1,2-dioeoyl-sn-glycero-3-phosphocholine (DOPC),
- 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),

1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine,
 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine,
 1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
 1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
 1,2-didocosaheptaenoyl-sn-glycero-3-phosphocholine,
 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),
 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine,
 1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
 1,2-didocosaheptaenoyl-sn-glycero-3-phosphoethanolamine,
 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1 -glycerol) sodium salt (DOPG),
 sphingomyelin, and
 combinations thereof.

12. The composition of claim 11, wherein the phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

13. The composition of any one of claims 1-12, wherein the composition further comprises at least one excipient, optionally wherein the excipient comprises sucrose.

14. The composition of any one of claims 1-13, wherein the composition does not comprise a lysophosphatidylcholine (LPC), optionally wherein the LPC has a single C13-C24 acyl chain.

15. A composition comprising:
 an mRNA complexed with one or more lipids (RNA-Lipoplex); and

wherein the mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the one or more lipids comprise a first lipid and a second lipid.

16. A composition comprising:
a first mRNA and a second mRNA complexed with one or more lipids (RNA-Lipoplex); and
wherein the first mRNA comprises a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the second mRNA comprises a coding region of an antigen, and the one or more lipids comprise a first lipid and a second lipid.

17. A composition comprising:
an mRNA complexed with one or more lipids (RNA-Lipoplex); and
wherein the mRNA comprises a first coding region and a second coding region separated by a 2A-like sequence, the first coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS) and the second coding region is a coding region of an antigen or the first coding region is a coding region of an antigen and the second coding region is a coding region of a constitutively active cyclic GMP-AMP synthase (cGAS), and the one or more lipids comprise a first lipid and a second lipid.

18. The composition of any one of claims 15-17, wherein the first lipid is a cationic lipid, and the second lipid is a neutral or anionic lipid.

19. The composition of claim 18, wherein the cationic lipid comprises one or both of:
i) 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) or analogs or derivatives thereof; and
ii) 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) or analogs or derivatives thereof.

20. The composition of claim 18 or claim 19, wherein the neutral or anionic lipid comprises:

i) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) or analogs or derivatives thereof; and/or
ii) cholesterol or analogs or derivatives thereof; and/or
iii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or analogs or derivatives thereof.

21. The composition of any one of claims 1-20, further comprising a TLR7/8 agonist.
22. The composition of claim 21, wherein the TLR7/8 agonist is a small molecule with a molecule weight of 900 daltons or less.
23. The composition of claim 22, wherein the TLR7/8 agonist comprises an imidazoquinoline compound.
24. The composition of claim 23, wherein the TLR7/8 agonist comprises resiquimod (R848).
25. The composition of any one of claims 1-24, wherein the mRNA or the first mRNA and the second mRNA comprises a 5' untranslated region (5'UTR) and a 3' untranslated region (3'UTR).
26. The composition of any one of claims 1-25, wherein the mRNA comprises a 5' cap structure.
27. The composition of any one of claims 1-26, wherein the mRNA comprises a polyA tail.
28. The composition of any one of claims 1-27, wherein the mRNA is a nucleoside-modified mRNA.
29. The composition of any one of claims 1-28, wherein the constitutively-active cGAS has a greater propensity to self DNA reactivity than its wild-type counterpart.
30. The composition of any one of claims 1-29, wherein the cGAS is a truncated cGAS devoid of an amino-terminal phosphoinositide-binding domain (cGAS Δ N).
31. The composition of claim 30, wherein the cGAS Δ N comprises the amino acid sequence of SEQ ID NO:1 or the amino acid sequence at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1.

32. The composition of claim 31, wherein the cGASΔN comprises:
- (i) the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, or the amino acid sequence at least 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8; or
 - (ii) the consensus amino acid sequence of SEQ ID NO:9.
33. The composition of claim 31, wherein the cGASΔN is encoded by the nucleotide sequence of SEQ ID NO:17.
34. The composition of any one of claims 30-33, wherein the coding region of the cGASΔN is in operable combination with a start codon (ATG).
35. The composition of any one of claims 1-34, wherein the antigen is a tumor antigen.
36. The composition of claim 35, wherein the tumor antigen is a tumor-associated antigen.
37. The composition of claim 35, wherein the tumor antigen is a neoantigen.
38. The composition of any one of claims 1-34, wherein the antigen comprises a microbial antigen.
39. The composition of claim 38, wherein the microbial antigen comprises a viral antigen, a bacterial antigen, a protozoan antigen, or a fungal antigen.
40. The composition of any one of claims 1-34, wherein the antigen comprises a surface protein or fragment thereof of a pathogen.
41. The composition of claim 40, wherein the pathogen is capable of causing disease in human subjects.
42. The composition of claim 40 or claim 41, wherein the pathogen is a virus.

43. The composition of claim 42, wherein the virus is a SARS-CoV-2.
44. The composition of claim 43, wherein the antigen is a spike (S) glycoprotein of the SARS-CoV-2, optionally wherein the spike glycoprotein is a pre-fusion stabilized variant.
45. The composition of any one of claims 1-44, wherein the composition does not comprise lipopolysaccharide (LPS) or monophosphoryl lipid A (MPLA).
46. The composition of any one of claims 1-45, wherein the composition does not comprise oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC) or a species of oxPAPC.
47. The composition of claim 46, wherein the composition does not comprise 2-[[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium(HOdiA-PC), [(2R)-2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-hexadecanoyloxypropyl] 2- (trimethylazaniumyl)ethyl phosphate (KOdiA-PC), 1-palmitoyl-2-(5-hydroxy-8-oxo-octenoyl)-sn-glycero-3-phosphorylcholine (HOOA-PC), 2-[[[(2R)-2-[(E)-5,8-dioxooct-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium (KOOA-PC), [(2R)-3-hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2- (trimethylazaniumyl)ethyl phosphate (POVPC), [(2R)-2-(4-carboxybutanoyloxy)-3-hexadecanoyloxy propyl] 2- (trimethylazaniumyl)ethyl phosphate (PGPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[2-[(Z)-oct-2-enyl]-5-oxocyclopent-3-en-1-ylidene]methyl]oxiran-2-yl]butanoyloxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate (PECPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[3-hydroxy-2-[(Z)-oct-2-enyl]-5-oxocyclopentylidene]methyl]oxiran-2-yl]butanoyloxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate (PEIPC) and/or 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC).
48. A pharmaceutical formulation comprising the composition of any one of claims 1-47, and a pharmaceutically acceptable excipient.
49. A method for production of hyperactivated dendritic cells, the method comprising contacting the dendritic cells with an effective amount of the composition of any one of claims 1-47, any one of claims 21-47, or the formulation of claim 48 to produce hyperactivated dendritic

cells, wherein the hyperactivated dendritic cells secrete IL-1 β without undergoing cell death within about 48 hours of exposure.

50. The method of claim 49, wherein the dendritic cells are:

- (i) contacted in vivo with the composition; or
- (ii) contacted ex vivo with the composition.

51. The method of claim 49 or claim 50, wherein the hyperactivated dendritic cells:

- (i) secrete higher levels of one or more of RANTES, IP-10 and IFN α than unstimulated dendritic cells or dendritic cells contacted with empty LNPs; and/or
- (ii) express higher levels of at least one cell surface marker selected from the group consisting of CD40, CD86, CD69, MHC class II, MHC class I, CCR7, and combinations thereof.

52. A pharmaceutical formulation comprising at least 10^3 , 10^4 , 10^5 or 10^6 of the hyperactivated dendritic cells produced by the method of any one of claims 49-51, and a pharmaceutically acceptable excipient.

53. A method of stimulating an immune response against an antigen, comprising administering an effective amount of the pharmaceutical formulation of claim 48 or claim 52 to an individual in need thereof to stimulate the immune response against the antigen.

54. A method of treating cancer, comprising administering an effective amount of the pharmaceutical formulation of claim 48 or claim 52 to an individual in need thereof to treat the cancer.

55. A method of inhibiting abnormal cell proliferation, comprising administering an effective amount of the pharmaceutical formulation of claim 48 or claim 52 to an individual in need thereof to inhibit abnormal cell proliferation.

56. A method of treating or preventing an infectious disease, comprising administering an effective amount of the pharmaceutical formulation of claim 48 to an individual in need thereof to treat or prevent the infectious disease.

57. The method of claim 56, wherein the infectious disease is a viral disease.

58. The method of claim 56, wherein the infectious disease is a bacterial disease.
59. The method or pharmaceutical formulation of any one of claims 49-55, wherein the dendritic cells are mammalian cells.
60. The method or pharmaceutical formulation of claim 59, wherein the mammalian cells are human cells.
61. The method of any one of claims 53-59, wherein the individual is mammal.
62. The method of claim 61, wherein the mammal is a human.
63. The method of claim 61, wherein the mammal is a dog or a cat.
64. The composition, formulation, or method of any one of claims 1-63, wherein the phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and the least one lipid comprises 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester (SM-102) or analogs or derivatives thereof, and cholesterol.
65. The composition, formulation, or method of claim 64, wherein the at least one lipid further comprises a pegylated lipid, optionally wherein the pegylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG].
66. The composition, formulation, or method of any one of claims 1-65, wherein the LNP has an effective diameter of less than about 250 nanometers, optionally from about 25 to about 250 nanometers, optionally from about 50 to about 200 nanometers, or optionally from about 75 to about 175 nanometers.
67. The composition, formulation, or method of claim 66, wherein the LNP has an effective diameter of less than about 200 nanometers.
68. The composition, formulation, or method of claim 67, wherein the LNP has an effective diameter of less than about 150 nanometers.

FIG. 1

M_mulatta	PGARKLRVLEKLRRLSHQDISKAAKVNVGVGHLLRLK-CEPEFGGVEQLHTGSYYEHV	59
P_anubis	PGARKLRVLEKLRRLSHQDISKAAKVNVGVGHLLRLK-CESEFEGVEQLHTGSYYEHV	59
N_leucogenys	PGARKLRVLEKLRRLSRQEISEAAEVNVGVVDHLLRLQKCDSEFRGVGLLRTGSYYEHV	60
H_lar	PGARKLRVLEKLRRLSRQEICEAAEVNVGVVDHLLRLQKCDSEFRGVGLLRTGSYYEHV	60
P_abelii	PGASKLRVLEKLRRLSRLEISKAAEVNVGVVDHLLRLQKYNSEFRGVGLLRTGSYYEHV	60
P_troglodytes	PGASKLRVLEKLRRLSRDDISTAAGMVKGVDHLLRLK-CDSAFRGVGLLNTGSYYEHV	59
G_gorilla	PGASKLRVLEKLRRLSRDDISTAAGMVKGVDHLLRLK-CDSAFRGVGLLNTGSYYEHV	59
H_sapiens	PGASKLRVLEKLRRLSRDDISTAAGMVKGVDHLLRLK-CDSAFRGVGLLNTGSYYEHV	59
	*** ** *****;*: :*. ** :*: **.* ** : : * ** *.*****	
Consensus	PGAXKLxAVLEKLxLSxxxIzzAAxxVxxVVxHLLxRLxxxxxxFxGVzzLxTGSYYEHV	
M_mulatta	KISAPNEFDVMFKLQVPRIQLEEYSNTGAYYFVKFKRNPENPLSLFLEDEILSASKMLS	119
P_anubis	KISAPNEFDVMFKLQVPRIQLEEYSNTGAYYFVKFKRNPENPLSQFLEDEILSASKMLS	119
N_leucogenys	KISAPNEFDVMFKLEVPRIQLEEYSNTGAYYFVKFKRNPENPLSQFLEGEILSASKMLS	120
H_lar	KISAPNEFDVMFKLEVPRIQLEEYSNTGAYYFVKFKRNPENPLCQFLEGEILSASKMLS	120
P_abelii	KISAPNEFDVMFKLEVPRIQLEEYSNTGAYYFVKFKRNPENPLSQFLEGEILSASKMLS	120
P_troglodytes	KISAPNEFDVMFKLEVPRIQLEEYSNTRAYYFVKFKRNPENPLSQFLEGEILSASKMLS	119
G_gorilla	KISAPNEFDVMFKLEVPRIQLEEYSNTRAYYFVKFKRNPENPLSQFLEGEILSASKMLS	119
H_sapiens	KISAPNEFDVMFKLEVPRIQLEEYSNTRAYYFVKFKRNPENPLSQFLEGEILSASKMLS	119
	*****;*: *****;* *****; ***. ***.*****	
Consensus	KISAPNEFDVMFKLxVPRIQLEEYSxTxAYYFVKFKRNPxxNPLxxFLEzEILSASKMLS	
M_mulatta	KFRKIIKEEINNIKDVPDADVIMKRKRGGSPAVTLLINKEISVDITLALCLK-TSWPAS	178
P_anubis	QFRKIIKEEINNIKD----TDVIMKRKRGGSPAVTLLINKEISVDITLALCLK-TSWPAS	174
N_leucogenys	KFRKIIKEEINNIKD----TDVIMKRKRGGSPAVTLLISEKISVDITLALESNSNSWPAS	176
H_lar	KFRKIIKEEINNIKD----TDVILKRKRGGSPAVTLLISEKISVDITLALESKSSSWPAS	176
P_abelii	KFRKIIKEEINNIKD-----TDVIMKRKRGGSPAVTLLISEEISVDITLALESK-SSWPAS	175
P_troglodytes	KFRKIIKEEINNIK-----DVIMKRKRGGSPAVTLLISEKISVDITLALESK-SSWPAS	172
G_gorilla	KFRKIIKEEINNIKD----TDVIMKRKRGGSPAVTLLISEKISVDITLALESK-SSWPAS	174
H_sapiens	KFRKIIKEEINDIKD----TDVIMKRKRGGSPAVTLLISEKISVDITLALESK-SSWPAS	174
	:*****;*: *****;*: *****;*: *****;*: *****	
Consensus	xFRKIIKEEINxIKxxxxxxDVIxKRKRxGSPAVTLLIxIxISVDITLALExzzxxSWPAS	
M_mulatta	TQEGLAIKNWLSAKVRQQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILSNHGKS	238
P_anubis	TQEGLAIKNWLSAKVRQQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILSNHGKS	234
N_leucogenys	TQEGLPIKDWLSGKVRQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGKT	236
H_lar	TQEGLPIKDWLSGKVRTLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGET	236
P_abelii	TQEGLPIKNWLSAKVRKQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGKS	235
P_troglodytes	TQEGLPIKNWLSAKVRKQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGKS	232
G_gorilla	TQEGLRIQNWLSAKVRQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGKS	234
H_sapiens	TQEGLRIQNWLSAKVRKQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILNNHGKS	234
	***** *:;***.*** *****;*: *****;*: *****;*: *****;*: *****	
Consensus	TQEGLxIxWLSxKVRxQLRLKPFYLVPKHAKGNGFQEETWRLSFSHIEKEILxNHGxx	

M_mulatta	KTCCENKEMKCCRKDCLKLMKYILLEQLKEKFCDKKHLDKFSSYHVKTAFHHLCTENPQDS	298
P_anubis	KTCCENKEMKCCRKDCLKLMKYILLEQLKEKFCDKKHLDKFSSYHVKTAFHHLCTENPQDS	294
N_leucogenys	KTCCENKNVCKCRKDCLKLMKYILLEQLKERFKDKKHLDKFSSYHVKTAFHHVCTENPQDS	296
H_lar	KTCCENKKVKCCRKDCLKLMKYILLEQLKERFKDKKHLDKFSSYHVKTAFHHVCTENPKDS	296
P_abelii	KTCCEDKEVKCCRKDCLKLMKYILLEQLKERFKDKKHLDKFSSYHVKTAFHHVCTQNPDQS	295
P_troglodytes	KTCCEIKEAKCCRKDCLKLMKYILLEQLKEKFCDKKHLDKFSSYHVKTAFHHVCTENPQDS	292
G_gorilla	KTCCENKEAKCCRKDCLKLMKYILLEQLKERFKDKKHLDKFSSYHVKTAFHHVCTQNPDQS	294
H_sapiens	KTCCENKEEKCCRKDCLKLMKYILLEQLKERFKDKKHLDKFSSYHVKTAFHHVCTQNPDQS	294
	***** *: *****;*****;*****;*:**:*	
Consensus	KTCCExKxxKCCRKDCLKLMKYILLEQLKExFCDKKHLDKFSSYHVKTAFHxCTxNPxDs	
M_mulatta	QWDPKDLGLCFDNCVTYFLECLRTEQLKNYFIPGFNLFSSNLIDKTSKEFLSKQIEYERN	358
P_anubis	QWDPKDLGLCFDNCVTHFLQCLRTKLANYFIPGFNLFSSNLIDKSSKEFLSKQIEYERN	354
N_leucogenys	QWDPKNLGFCFDKCVIYFLKCLRTEQLGNFYIPGFNLFSSNLIDKRSKEFLSKQIEYERN	356
H_lar	QWDPKDLGLCFDKCVIYFLQCLSTEQLGNFYIPGFNLFSSNLIDKRSKEFLSKQIEYERN	356
P_abelii	QWDPKDLGLCFDNCVTYFLQCLRTEQLGNFYIPGFNLFSSNLIDKRSKEFLTQIEYERN	355
P_troglodytes	QWDRKDLGLCFDNCVTYFLQCLRIEKENLYFIPEFNLFSSDLIDKRSKEFLTQIEYERN	352
G_gorilla	QWDRKDLGLCFDNCVTYFLQCLRTERLENLYFIPEFNLFSSRLIDKRSKEFLTQIEYERN	354
H_sapiens	QWDRKDLGLCFDNCVTYFLQCLRTEKENLYFIPEFNLFSSNLIDKRSKEFLTQIEYERN	354
	*** **;*:**;*:**:* **:* ***** :**** *:**;*****	
Consensus	QWDxKxLGxCFDxCVTxFLxCLxxExLxNYFIPxFNLFsxxLIDKxSKEFLxKQIEYERN	
M_mulatta	NEFPVFGEF	367
P_anubis	NEFPVFGEF	363
N_leucogenys	NEYPVFG--	363
H_lar	NEYPVFGKC	365
P_abelii	NEFPVFDEF	364
P_troglodytes	NEFPVFDEF	361
G_gorilla	NEFPVFDEF	363
H_sapiens	NEFPVFDEF	363
	**:*:	
Consensus	NExPVFxxx	

FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A




FIG. 4B





FIG. 4C



○ Controls ■ LNPs

FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E





FIG. 5F



■ GenVoy ILM LNPs ◆ Custom Lipid Mix LNPs

FIG. 6A




FIG. 6B






FIG. 6C





● Controls ■ GenVoy ILM LNPs ◆ Custom Lipid Mix LNPs

FIG. 8A




FIG. 8B




FIG. 8C






FIG. 8D





○ Media ▨ R848 ◆ R848 + MCC950

FIG. 10A





FIG. 10B



□ 1 ug/mouse ■ 5 ug/mouse

FIG. 11A




FIG. 11B




FIG. 11C





FIG. 11D












FIG. 13A





FIG. 13B



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2023/066974

A. CLASSIFICATION OF SUBJECT MATTER		
INV.	A61K39/00	A61K39/39
	C12N9/12	C12N15/88
		A61P37/00
		A61P37/04
		C12N9/00
ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
A61K A61P C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2020/006038 A1 (DANA FARBER CANCER INST INC [US]; KRANZUSCH PHILIP J [US]) 2 January 2020 (2020-01-02) see opinion for details -----	1-68
Y	WO 2016/170176 A1 (CUREVAC AG [DE]) 27 October 2016 (2016-10-27) see opinion for details -----	1-68
Y	WO 2021/250263 A1 (ETHERNA IMMUNOTHERAPIES NV [BE]) 16 December 2021 (2021-12-16) see opinion for details -----	1-68
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
12 October 2023		20/10/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Landré, Julien

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2023/066974

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed.
 - b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13*ter*.1(a)).
☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2023/066974

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2020006038	A1	02-01-2020	AU 2019294632	A1 04-02-2021
			CA 3104515	A1 02-01-2020
			EP 3814487	A1 05-05-2021
			US 2021324351	A1 21-10-2021
			WO 2020006038	A1 02-01-2020

WO 2016170176	A1	27-10-2016	AU 2016251687	A1 24-08-2017
			AU 2020220157	A1 10-09-2020
			BR 112017018368	A2 17-04-2018
			CA 2975333	A1 27-10-2016
			CN 108064176	A 22-05-2018
			DK 3173092	T3 05-08-2019
			DK 3326641	T3 30-09-2019
			EP 3173092	A2 31-05-2017
			EP 3326641	A1 30-05-2018
			EP 3603661	A2 05-02-2020
			ES 2746340	T3 05-03-2020
			ES 2753259	T3 07-04-2020
			JP 6912384	B2 04-08-2021
			JP 2018517674	A 05-07-2018
			JP 2021178827	A 18-11-2021
			KR 20170138548	A 15-12-2017
			RU 2017140468	A 22-05-2019
			SG 10201907164S	A 27-09-2019
			SG 11201707832R	A 29-11-2017
			TW 201704250	A 01-02-2017
			US 2016331844	A1 17-11-2016
			US 2018207295	A1 26-07-2018
			US 2019054189	A1 21-02-2019
			US 2019151469	A1 23-05-2019
			WO 2016170176	A1 27-10-2016

WO 2021250263	A1	16-12-2021	AU 2021286911	A1 09-02-2023
			BR 112022025217	A2 03-01-2023
			CA 3186776	A1 16-12-2021
			CN 116133640	A 16-05-2023
			EP 4164596	A1 19-04-2023
			IL 298765	A 01-02-2023
			KR 20230050313	A 14-04-2023
			WO 2021250263	A1 16-12-2021
